Erlotinib Clinical Trials (2026): 698 Studies for Non-Small Cell Lung Cancer & Lung Cancer

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

698 Erlotinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 250 indications (including Non-Small Cell Lung Cancer & Lung Cancer) and 112,186 total planned enrollment. 77 Phase 3 Erlotinib trials and 352 Phase 2, 14 Phase 4 are listed. 12 Erlotinib clinical trials are actively recruiting at 6 U.S. sites across 4 states. Most recent activity: NCT06545695 (Jun 2031).

Where to Participate: All Erlotinib Trial Sites in the U.S. (6 sites across 4 states)

Every actively recruiting Erlotinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
GAEmory Saint Joseph's HospitalAtlanta30342NCT04981509Map
GAEmory University Hospital MidtownAtlanta30308NCT04981509Map
GAEmory University Hospital/Winship Cancer InstituteAtlanta30322NCT04981509Map
MDNCI - Center for Cancer ResearchBethesda20892NCT04981509Map
MNMayo Clinic in RochesterRochester55905NCT06997068Map
NCUniversity of North Carolina at Chapel Hill Lineberger Comprehensive Cancer CenterChapel Hill27599NCT06483555Map

Erlotinib clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedterminatedwithdrawnsuspendednot yet recruitingunknowntemporarily not availableTotal
Early P1213
P151081956143
P1/P22481552375
P2632256391144352
P2/P31326
P33501121177
P4921214
N/A111537128

Recruiting Erlotinib clinical trials (12)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06545695Epidermal Growth Factor Receptor Inhibition for KeratinopathiesP1/P2Epidermolytic Ichthyosis44Jul 2027
NCT04172779ECHO-BErlotinib for Hepatocellular Carcinoma ChemopreventionP2Cirrhosis, Liver60Dec 2026
NCT04341181ProTargetProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingP2Cancer300Aug 2020
NCT07418177Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMDP1/P2AMD - Age-Related Macular Degeneration9Feb 2026
NCT06997068Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationP2Metastatic Oral Cavity Carcinoma25Jul 2025
NCT04981509Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerP2Hereditary Leiomyomatosis and Renal Cell Carcinoma65Jun 2022
NCT02925234DRUPThe Drug Rediscovery Protocol (DRUP Trial)P2Cancer1,550Aug 2016
NCT06483555PANGEABasal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelP1/P2Pancreatic Adenocarcinoma104Feb 2025
NCT05525858KOSMOSIIKPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II—Solid Tumor1,000Sep 2022
NCT03297606CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)P2Lymphoma, Non-Hodgkin720Mar 2018
NCT06071013Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsP1/P2Non-small Cell Lung Cancer20Feb 2024
NCT05442060EGFRTo Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerP2Non-small Cell Lung Cancer60Jul 2022

Erlotinib clinical trials by indication

Lung Cancer (56)

NCTAcronymPhaseStatusTitle
NCT03628521—P1unknownFirst-line Combination Treatment Based on Anlotinib
NCT01248247—P2completedBATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
NCT01455389—P1/P2terminatedTUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
NCT01859026—P1completedA Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
NCT00436332S0635P2completedS0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
NCT01562028BELIEFP2completedBELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
NCT00100854—P2completedErlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00411632NSCLCP2completedBATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
+ 48 more, see All trials below.

Non-Small Cell Lung Cancer (55)

NCTAcronymPhaseStatusTitle
NCT04449874—P1active not recruitingA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT05834348DELINORN/AcompletedA Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
NCT02424617—P1/P2completedA Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
NCT02574078CheckMate370P1/P2completedA Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02013219NSCLCP1completedA Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT00130728—P3completedA Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
NCT02468661—P1terminatedA Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
NCT00563784NSCLCP2completedTARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
+ 47 more, see All trials below.

Pancreatic Cancer (37)

NCTAcronymPhaseStatusTitle
NCT02154737—P1completedGemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
NCT00769483—P1/P2completedMK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
NCT03403049—P1completedCarbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT00733746—P2completedGemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT00313560TARCEVAP2completedChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
NCT00614653—P1completedBevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
NCT00674973—P2completedA Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
NCT01782690—N/AcompletedAn Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
+ 29 more, see All trials below.

Non-small Cell Lung Cancer (32)

NCTAcronymPhaseStatusTitle
NCT00977470EGFRP2active not recruitingErlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
NCT06071013—P1/P2recruitingNintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
NCT05442060EGFRP2recruitingTo Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07271446PB101P1completedAn Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
NCT01407822EMERGINGP2/P3unknownErlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
NCT03653546BMP2/P3completedFirst Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
NCT01454102BMS-936558P1completedStudy of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT03074864TRENDP2/P3unknownTargeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC
+ 24 more, see All trials below.

Carcinoma, Non-Small-Cell Lung (30)

NCTAcronymPhaseStatusTitle
NCT01897480BaliseP2completedA Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
NCT01306045—P2completedMolecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
NCT02655536BRILLIANTP2unknownBevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
NCT00835471NVALT10P2completed2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
NCT03460678—P4terminatedRandomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
NCT01523587BIBW 2992P3completedLUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
NCT02146118—P2unknownA Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
NCT01900652ChimeP2completedA Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
+ 22 more, see All trials below.

Non Small Cell Lung Cancer (24)

NCTAcronymPhaseStatusTitle
NCT02152631JUNIPERP3active not recruitingA Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT03647592—N/AunknownReal World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
NCT06675695NCT02296125N/AcompletedEmulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases
NCT03123484—P2unknownβ-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
NCT01573702EGFRP2completedStereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
NCT02117024HS-110P2terminatedA Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
NCT02037997—P2unknownSafety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
NCT01487265—P2completedTrial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
+ 16 more, see All trials below.

Non-Squamous Non-Small Cell Lung Cancer (21)

NCTAcronymPhaseStatusTitle
NCT01260181—P2completedA Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
NCT01378962TRIGGERP2completedA Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
NCT01310036EGFRP2completedA Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
NCT01174563—P2completedA Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
NCT01351415NSCLCP3completedA Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
NCT01836133ELEMENTN/AcompletedAn Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)
NCT01456325—P3completedA Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
NCT01328951NSCLCP3completedA Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
+ 13 more, see All trials below.

Cancer (18)

NCTAcronymPhaseStatusTitle
NCT04341181ProTargetP2recruitingProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
NCT02925234DRUPP2recruitingThe Drug Rediscovery Protocol (DRUP Trial)
NCT02239952—N/AunknownHGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
NCT02714530ThoRaTP2terminatedThoracal Radiotherapy and Tarceva
NCT01636908ICKN/AcompletedDetermination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
NCT01518621RadErP2terminatedWhole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer
NCT01376310—P2terminatedGSK1120212 Rollover Study
NCT02889692—P3completedClinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
+ 10 more, see All trials below.

Head and Neck Cancer (18)

NCTAcronymPhaseStatusTitle
NCT01927744—P2completedStudy of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
NCT00573989—P1/P2terminatedIntensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
NCT00400374—P1completedSecondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
NCT00304278SCCAP2completedStudy of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
NCT00720304—P2completedErlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
NCT00570232UAB0718P2completedUAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
NCT00601913—Early P1completedErlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
NCT00779389—P1completedComparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family
+ 10 more, see All trials below.

Breast Cancer (15)

NCTAcronymPhaseStatusTitle
NCT00600496ARRY-142886P1completedA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
NCT04591431ROMEP2unknownThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
NCT00491816—P2unknownErlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
NCT01650506—P1completedStudy of Erlotinib and Metformin in Triple Negative Breast Cancer
NCT00834678—P1/P2completedBendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
NCT00054275—P2completedErlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
NCT00033514—P1/P2completedTrastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
NCT00503841—N/AterminatedErlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
+ 7 more, see All trials below.

Recurrent Non-small Cell Lung Cancer (10)

NCTAcronymPhaseStatusTitle
NCT01911507—P1completedINC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
NCT00499655—P2completedErlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
NCT01839955—P1completedErlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer
NCT01928160—P2withdrawnPemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
NCT00976677—P2terminatedCarboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
NCT00778167—P1/P2completedErlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00088959—P1completedCelecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00085280—N/AcompletedErlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
+ 2 more, see All trials below.

Advanced Solid Tumors (8)

NCTAcronymPhaseStatusTitle
NCT01190241TSAPN/AterminatedTargeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study
NCT01472016—P1completedStudy of ABT-700 in Subjects With Advanced Solid Tumors
NCT02057380—P2completedA Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
NCT01284335—P1terminatedA Safety Study in Participants With Advanced Solid Tumors
NCT00591383—P1unknownPhase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
NCT00739453—P1completedA Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
NCT00603356—P1completedPhase I Study of OSI-930 and Erlotinib in Cancer Tumors
NCT00139620—P1completedA Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Colorectal Cancer (8)

NCTAcronymPhaseStatusTitle
NCT00940316—P2completedDual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
NCT01229813ACT2P3completedAvastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
NCT00118261—P1completedErlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
NCT01135498—P2completedA Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
NCT00116506—P2completedStudy of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
NCT00265824DREAMP3completedOptimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
NCT00049101—P1/P2completedErlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00047762—P1completedSafety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

Solid Tumors (7)

NCTAcronymPhaseStatusTitle
NCT05904457BRISKP2unknownA Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
NCT02942095—P1completedStudy of Ixazomib and Erlotinib in Solid Tumors
NCT01197170—P1completedHormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
NCT00770263—P1completedErlotinib and Temsirolimus for Solid Tumors
NCT01602289—P1completedA Study of LY2875358 in Japanese Participants With Advanced Cancer
NCT01009073—P1completedA Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
NCT00495872—P1completedValproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Brain and Central Nervous System Tumors (7)

NCTAcronymPhaseStatusTitle
NCT00720356—P2completedBevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT00124657—P1/P2completedErlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
NCT00509431—P1completedErlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
NCT00086879—P2completedErlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00227032—P1terminatedErlotinib in Treating Patients With Progressive Glioblastoma Multiforme
NCT00360854—P1unknownErlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
NCT00054496—P2unknownErlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

Neoplasms (6)

NCTAcronymPhaseStatusTitle
NCT06161558—P1withdrawnErlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
NCT02091141—P2completedMy Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
NCT01482377HER3P1completedA Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
NCT00811993—P1terminatedA Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
NCT00954512—P1/P2terminatedStudy of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
NCT00207077—P1completedStudy of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

NSCLC (6)

NCTAcronymPhaseStatusTitle
NCT04575415BELLAN/AunknownBevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
NCT02795884—P3withdrawnAdjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
NCT02759614—P3completedCompare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
NCT02140333—P3unknownErlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
NCT01221077NSCLCP2completedStudy of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
NCT00283634—P2terminatedA Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Lung Adenocarcinoma (5)

NCTAcronymPhaseStatusTitle
NCT03076164—P1/P2completedA Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
NCT02399566—P4unknownClinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
NCT00126581—P2completedErlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
NCT01578668—P2completedErlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
NCT00716456—P1/P2completedCetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Metastatic Colorectal Cancer (5)

NCTAcronymPhaseStatusTitle
NCT02723578—P2completedPemetrexed and Erlotinib for Metastatic Colorectal Cancer
NCT00598156ACTP3completedChemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva
NCT00642746—P2terminatedErlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
NCT00784667DuxP2unknownDual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib
NCT00459901—P2terminatedStudy of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

Non-small-cell Lung Cancer (5)

NCTAcronymPhaseStatusTitle
NCT02095782INNOVATEP2terminatedChemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation
NCT01763385TRACTSP2unknownErlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases
NCT01069757—P1completedA Study of ARQ 197 in Combination With Erlotinib
NCT01377376ATTENTIONP3terminatedA Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
NCT00749567—P2terminatedCombination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma (5)

NCTAcronymPhaseStatusTitle
NCT01801111RO5424802P1/P2completedA Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
NCT01047059MIMEBP2completedMolecular Imaging With Erlotinib and Bevacizumab
NCT00602030—P1/P2completedStudy to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
NCT00444015NSCLCP1completedPhase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT00095225—P2completedA Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Carcinoma, Non-small-cell Lung (5)

NCTAcronymPhaseStatusTitle
NCT00125359—P2completedStudy of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
NCT00983307RTP2completedA Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
NCT00654420MK-0646P2completedA Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)
NCT00125372—N/AcompletedStudy of Tarceva and Targretin in Stage I-II Lung Cancer
NCT00036647—P3completedOSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Esophageal Cancer (5)

NCTAcronymPhaseStatusTitle
NCT00524121—P2completedErlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
NCT00393068—P2completedChemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
NCT00539617—P2terminatedChemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
NCT00566800—P1unknownErlotinib in Treating Patients With Barrett Esophagus
NCT00032123—P2completedErlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Pancreatic Adenocarcinoma (4)

NCTAcronymPhaseStatusTitle
NCT06483555PANGEAP1/P2recruitingBasal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
NCT01013649—P3completedGemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01389440GEMCAD1003P2completedEfficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
NCT00728000—P2withdrawnPhase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

Carcinoma, Non-small Cell Lung (4)

NCTAcronymPhaseStatusTitle
NCT03529084EGF816P3withdrawnPhase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
NCT02775006—P3terminatedDocetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
NCT00385996—P2completedPilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
NCT00729742MK0646P1completedPhase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Recurrent Non-Small Cell Lung Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT03137771—P2active not recruitingMaintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT01866410—P2completedCabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
NCT01193881—P1terminatedRO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
NCT00738881MARVELP3terminatedPemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Advanced Cancers (4)

NCTAcronymPhaseStatusTitle
NCT01532011—P1completedErlotinib in Combination With Pralatrexate in Advanced Malignancies
NCT01432119—P1withdrawnPhase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
NCT00903734EGFRP1completedAn Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status
NCT00895362—P1completedErlotinib in Combination With Cetuximab

Adenocarcinoma of the Lung (4)

NCTAcronymPhaseStatusTitle
NCT01259089—P1/P2completedHsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
NCT01557959—P2completedDocetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00087412S0341P2completedS0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
NCT00042835—P1terminatedErlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

Liver Cancer (4)

NCTAcronymPhaseStatusTitle
NCT01180959HCCP2completedErlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
NCT00881751—P2completedBevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
NCT00605722—P2completedA Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
NCT00293436—P1/P2withdrawnCelecoxib and Erlotinib in Treating Patients With Liver Cancer

Metastatic Pancreatic Cancer (4)

NCTAcronymPhaseStatusTitle
NCT01608841—P2unknownThe Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
NCT01303029GECAP2completedSafety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer
NCT00954525—P1completedIntravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
NCT00922896—P2completedTrial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

Adult Anaplastic Astrocytoma (4)

NCTAcronymPhaseStatusTitle
NCT00112736—P1/P2completedErlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
NCT01103375—P1terminatedErlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
NCT00045110—P1/P2completedErlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
NCT00030498—P1completedErlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Advanced Cancer (4)

NCTAcronymPhaseStatusTitle
NCT00543504—P1completedBevacizumab in Multiple Phase I Combinations
NCT01287546—P1completedA Study of LY2875358 in Participants With Advanced Cancer
NCT00895687—P1completedStudy of Erlotinib in Combination With Bortezomib
NCT00895128—P1completedStudy of Erlotinib in Combination With Dasatinib

Glioblastoma (4)

NCTAcronymPhaseStatusTitle
NCT00609999—P1completedPh I Dasatinib + Erlotinib in Recurrent MG
NCT00671970MGP2completedPhase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
NCT00672243—P2completedPh II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
NCT00337883—P2completedA Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

Hepatocellular Carcinoma (4)

NCTAcronymPhaseStatusTitle
NCT00832637Gem-oxP2terminatedGemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
NCT00242502—P2completedEfficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
NCT00287222—P2completedBevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
NCT00532441—P2terminatedErlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Unspecified Adult Solid Tumor, Protocol Specific (4)

NCTAcronymPhaseStatusTitle
NCT00276575—P1completedBevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
NCT00320073—P1completedVinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00126620—P1completedSorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00042809—P1completedErlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Prostate Cancer (4)

NCTAcronymPhaseStatusTitle
NCT00203424—P2completedTreatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
NCT00996502—P1/P2terminatedStudy of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
NCT00148772PSAP2completedStudy of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
NCT00087035—P2completedDocetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Fallopian Tube Cancer (4)

NCTAcronymPhaseStatusTitle
NCT00126542—P2completedBevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00030446—P2completedErlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00263822—P3completedErlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
NCT00217529—P1/P2completedErlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Recurrent Lung Non-Small Cell Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT01708954—P2active not recruitingErlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT00254384—P1completedDocetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
NCT02535338—P1/P2completedErlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Non-Small-Cell Lung Cancer (3)

NCTAcronymPhaseStatusTitle
NCT02031601TCL-1P4unknownIntercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
NCT02495233EGFRP1/P2terminatedA Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
NCT00550173—P2completedA Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung (3)

NCTAcronymPhaseStatusTitle
NCT02098954—P2unknownErlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers
NCT00457392—P3completedA Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
NCT00281021—P2terminatedSecond Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

Metastatic Pancreatic Adenocarcinoma (3)

NCTAcronymPhaseStatusTitle
NCT01660971—P1active not recruitingGemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT01729481ML22774P2unknownGemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer
NCT01204372GATE 1P2completedTrial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma

Non-small Cell Lung Cancer Metastatic (3)

NCTAcronymPhaseStatusTitle
NCT01471964—P1/P2terminatedStudy to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
NCT01320501REALMEP4suspendedExperience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
NCT00701558—P2completedA Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT01316757—P2completedCarboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT00101348—P1/P2completedErlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
NCT00049283—P1completedErlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Adenocarcinoma of the Pancreas (3)

NCTAcronymPhaseStatusTitle
NCT01222689—P2completedSelumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00091026—P2completedBevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
NCT00063947—P1completedErlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Myelodysplastic Syndrome (3)

NCTAcronymPhaseStatusTitle
NCT01085838—P1/P2completedErlotinib in Higher Risk Myelodysplastic Syndrome
NCT00977548MDSP2completedErlotinib Study for Myelodysplastic Syndrome (MDS)
NCT00570375EGFRP2withdrawnThe Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

Squamous Cell Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT00966472—P1completedPhase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
NCT01009203—P2terminatedTemsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
NCT00476476—P2completedErlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Adult Giant Cell Glioblastoma (3)

NCTAcronymPhaseStatusTitle
NCT00335764—P1/P2completedSorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
NCT00445588—P2completedErlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
NCT00039494—P2completedErlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

Adult Primary Hepatocellular Carcinoma (3)

NCTAcronymPhaseStatusTitle
NCT00365391—P2completedBevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
NCT00047346—P1completedErlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
NCT00047333—P2terminatedErlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

Solid Tumor (2)

NCTAcronymPhaseStatusTitle
NCT05525858KOSMOSIIN/ArecruitingKPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
NCT02488330—P3completedAn Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

EGFR Gene Mutation (2)

NCTAcronymPhaseStatusTitle
NCT03720873—P2unknownEGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
NCT02886195effectP3unknownEGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Metastatic Non-Small Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT02411448RELAYP3active not recruitingA Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT01395758ARQ 197P2completedErlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Diffuse Intrinsic Pontine Glioma (2)

NCTAcronymPhaseStatusTitle
NCT02233049BIOMEDEP2unknownBiological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
NCT01182350DIPGP2terminatedMolecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Brain Cancer (2)

NCTAcronymPhaseStatusTitle
NCT01257594—P1completedEGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
NCT01110876GBMP1/P2terminatedPhase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Stage III Squamous Cell Carcinoma of the Hypopharynx (2)

NCTAcronymPhaseStatusTitle
NCT01192815—P2terminatedErlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
NCT00410826—P2completedCisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Non Small Cell Lung Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT01229150NSCLCP2completedRandomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
NCT00592007—P2terminatedStudy Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Extrahepatic Bile Duct Cancer (2)

NCTAcronymPhaseStatusTitle
NCT00987766—P1completedGemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
NCT00266097—P1completedOxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

Ovarian Cancer (2)

NCTAcronymPhaseStatusTitle
NCT00520013CTAP2completedAvastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
NCT01003938—P2terminatedTopotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Neuroendocrine Tumors (2)

NCTAcronymPhaseStatusTitle
NCT00843531—P2terminatedRAD001 and Erlotinib in Patients With Neuroendocrine Tumors
NCT00947167—P2terminatedA Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Adult Solid Neoplasm (2)

NCTAcronymPhaseStatusTitle
NCT00878163—P1active not recruitingGDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
NCT00045201—P1active not recruitingErlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Advanced Non-Small Cell Lung Cancer (2)

NCTAcronymPhaseStatusTitle
NCT00349219TORCHP3completedTORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer
NCT00783471DOPERLOP2terminatedDocetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)

Rectal Cancer (2)

NCTAcronymPhaseStatusTitle
NCT00543842—P1completedBevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
NCT00307736—P1/P2completedBevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Adenocarcinoma of the Esophagus (2)

NCTAcronymPhaseStatusTitle
NCT01561014—P1completedOxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00045526—P2completedErlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Metastatic Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT00570258MBCP2terminatedRandomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
NCT00597597—P2terminatedPhase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Adenocarcinoma of the Colon (2)

NCTAcronymPhaseStatusTitle
NCT00397384—P1completedErlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
NCT00032110—P2completedErlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Lung Neoplasms (2)

NCTAcronymPhaseStatusTitle
NCT01130753—P2completedEfficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer
NCT00339586—P2unknownFirst-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Renal Cell Carcinoma (2)

NCTAcronymPhaseStatusTitle
NCT00353301—P2completedErlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
NCT00081614—P2completedA Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma

Bladder Cancer (2)

NCTAcronymPhaseStatusTitle
NCT00380029—P2completedErlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
NCT00088946—P2completedErlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Epidermolytic Ichthyosis (1)

NCTAcronymPhaseStatusTitle
NCT06545695—P1/P2not yet recruitingEpidermal Growth Factor Receptor Inhibition for Keratinopathies

Cirrhosis, Liver (1)

NCTAcronymPhaseStatusTitle
NCT04172779ECHO-BP2not yet recruitingErlotinib for Hepatocellular Carcinoma Chemoprevention

AMD - Age-Related Macular Degeneration (1)

NCTAcronymPhaseStatusTitle
NCT07418177—P1/P2not yet recruitingStudy in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD

Metastatic Oral Cavity Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT06997068—P2recruitingMethotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Triple Negative Breast Cancer (TNBC) (1)

NCTAcronymPhaseStatusTitle
NCT05827614POTENTIATEP1terminatedStudy of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Hereditary Leiomyomatosis and Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT04981509—P2recruitingTesting of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Biliary Tract Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03110484BTCP2unknownPemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Non-Small Cell Lung Cancer Stage IIIA (1)

NCTAcronymPhaseStatusTitle
NCT04455594ANSWERP2unknownAlmonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCTAcronymPhaseStatusTitle
NCT03878524SMMARTP1terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Lung Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT05081674BLISSP2completedBrazilian Lung Immunotherapy Study

Non-squamous, Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04179890UpSwinGN/AcompletedThe Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

Advanced Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT04165031—P1/P2terminatedA Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Cancer of Unknown Primary Site (1)

NCTAcronymPhaseStatusTitle
NCT03498521CUPISCOP2completedA Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Lymphoma, Non-Hodgkin (1)

NCTAcronymPhaseStatusTitle
NCT03297606CAPTURP2recruitingCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Attenuated Familial Adenomatous Polyposis (1)

NCTAcronymPhaseStatusTitle
NCT02961374—P2completedErlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Pancreatic Adenocarcinoma Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT03213626—P2terminatedCabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Rare Tumor (1)

NCTAcronymPhaseStatusTitle
NCT03239015—P2unknownEfficacy and Safety of Precision Therapy in Refractory Tumor

Lung Cancer, Nonsmall Cell (1)

NCTAcronymPhaseStatusTitle
NCT02991651—P1terminatedStudy of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

EGFR Positive Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03126799AvaTaP2unknownA Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Glioma (1)

NCTAcronymPhaseStatusTitle
NCT02689336—P2withdrawnErlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Epidermal Growth Factor Receptor (1)

NCTAcronymPhaseStatusTitle
NCT02770014—P2terminatedRapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Nonsmall Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT03050411—P1unknownApatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02633189BEVERLYP3unknownStudy Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Pancreatic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT02737228—P1/P2unknownStudy of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Non-small Cell Lung Cancer (NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT02588261SOLARP3terminatedA Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Relapsed Pediatric Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT02638428—P2unknownGenomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Non-Small Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02556593—P2terminatedIMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

Oligometastatic Lung Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02450591—N/AcompletedLocal Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Ebola Virus Disease (1)

NCTAcronymPhaseStatusTitle
NCT02380625EVDP1/P2unknownMultiple Treatments for Ebola Virus Disease (EVD)

Lung Non-Squamous Non-Small Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02193282—P3active not recruitingErlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Non - Small Cell Lung Cancer NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT02352948ARCTICP3completedA Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Solid Tumors and Hematologic Malignancy (1)

NCTAcronymPhaseStatusTitle
NCT02355431EGFRP2withdrawnItacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02296125FLAURAP3completedAZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Cirrhosis (1)

NCTAcronymPhaseStatusTitle
NCT02273362—P1/P2completedErlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

EGFR Mutated EGFR TKI Naive Metastatic NSCLC (1)

NCTAcronymPhaseStatusTitle
NCT02206763EGFRP1terminatedErlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Bladder Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02169284—P2terminatedErlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 (1)

NCTAcronymPhaseStatusTitle
NCT02194738—N/Aactive not recruitingGenetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

HIV Infection (1)

NCTAcronymPhaseStatusTitle
NCT02134886—P1terminatedErlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

Recurrent Squamous Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02154490—N/AcompletedLung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NSCLC Patients With EGFR Activating Mutation (1)

NCTAcronymPhaseStatusTitle
NCT02178397FLAREP3terminatedA Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

MET Positive (1)

NCTAcronymPhaseStatusTitle
NCT02926638—P2/P3terminatedLung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Non-small Cell Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02039674MK-3475P1/P2completedA Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Lung, Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT02066038EGFRP2unknownIntermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Advanced Solid Tumors Cancer (1)

NCTAcronymPhaseStatusTitle
NCT02099058PKP1active not recruitingA Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Relapsed / Recurrent Germ Cell Tumors (1)

NCTAcronymPhaseStatusTitle
NCT01962896—P2terminatedA Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

Gastrointestinal Cancers (1)

NCTAcronymPhaseStatusTitle
NCT02013089GITICN/AunknownA Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study

Recurrent Childhood Brain Tumor (1)

NCTAcronymPhaseStatusTitle
NCT02015728SEEDN/AunknownSelecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Stage IIIA Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01857271EVENTP2terminatedErlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer

Stage III Non-Small Cell Lung Cancer AJCC v7 (1)

NCTAcronymPhaseStatusTitle
NCT01822496—P2terminatedErlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Self Efficacy (1)

NCTAcronymPhaseStatusTitle
NCT01965275—P2unknownHigh-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

EGFR-Mutant Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01967095—P1completedLow Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Multiple Brain Metastases (1)

NCTAcronymPhaseStatusTitle
NCT01887795ENTERP3completedPhase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study

Advanced Stage Non Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01955421NSCLC EGFR TKIP2unknownErlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Chronic Hepatitis C Infection (1)

NCTAcronymPhaseStatusTitle
NCT01835938—P1/P2unknownClinical Investigation of Erlotinib as an HCV Entry Inhibitor

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1)

NCTAcronymPhaseStatusTitle
NCT01664897—P2completedErlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Esophageal Squamous Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01752205ESCC-307PLAHP3unknownPaclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma

Non Small Cell Lung Cancer, Oligometastatic (1)

NCTAcronymPhaseStatusTitle
NCT01796288ROLEP2unknownThe Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment

Reccurent/Metastatic Solid Tumor Disease (1)

NCTAcronymPhaseStatusTitle
NCT01771458SHIVAP2completedA Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

Non-small Cell Lung Cancer Stage III (1)

NCTAcronymPhaseStatusTitle
NCT01683175—P2unknownErlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Recurrent Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01688973—P2completedTivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Non-small Cell Lung Cancer (NSCLC), Recurrent (1)

NCTAcronymPhaseStatusTitle
NCT01515969TKI258P1terminatedPhase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

EGFR Mutation Positive Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01776684—N/AunknownEvaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Malignant Peritoneal Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT01592383—P2completedErlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Non-small Cell Lung Cancer(NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT02036359OncologyP2unknownErlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca

Stage IV Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01556191LADIEP2completedLung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR

EGFR Exon 19 Deletion Mutation (1)

NCTAcronymPhaseStatusTitle
NCT01532089—P2completedErlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Non Small-cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01402089—P4completedCytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

NSCLC Stage II (1)

NCTAcronymPhaseStatusTitle
NCT01470716—P2unknownNeoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Recurrent Skin Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01465815—P1/P2withdrawnPhase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Advanced Pancreatic Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01454180—P2completedStudy of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Pancreas Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT01693419—P2completedS-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Carcinoma，Non-Small-Cell Lung (1)

NCTAcronymPhaseStatusTitle
NCT01153984BIOTECP2completedA Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Non-small Cell Lung Cancer Stage IIIA (1)

NCTAcronymPhaseStatusTitle
NCT01410214—P2unknownErlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Ependymoma (1)

NCTAcronymPhaseStatusTitle
NCT01247922—P2terminatedSingle-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Recurrent Metastatic Squamous Neck Cancer With Occult Primary (1)

NCTAcronymPhaseStatusTitle
NCT01332279—P1withdrawnEverolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Metastatic Skin Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01198028—P2completedErlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy (1)

NCTAcronymPhaseStatusTitle
NCT01186861—P2completedPhase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Skin Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01059305SCCP2terminatedPhase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Adenosquamous Lung Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01294306—P2completedMK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Non Squamous, Non-small-cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01244191—P3terminatedTivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Advanced/Recurrent Non-small-cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01251796—P1completedA Study of ARQ 197 in Combination With Erlotinib

NSCLC (Advanced Non-small Cell Lung Cancer) (1)

NCTAcronymPhaseStatusTitle
NCT01211483U3-1287P1/P2completedStudy of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Recurrent or Refractory Pediatric Ependymoma (1)

NCTAcronymPhaseStatusTitle
NCT01032070PETEYP2terminatedErlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Locally Advanced Pancreatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01210911GEMP2completedMetformin Combined With Chemotherapy for Pancreatic Cancer

Leukemia, Myelomonocytic, Acute (1)

NCTAcronymPhaseStatusTitle
NCT01174043—P2completedPilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Neoplasms, Lung (1)

NCTAcronymPhaseStatusTitle
NCT01131429—P2unknownA Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Hormone-sensitive Metastatic Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01205685—P2terminatedEndocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

HLRCC (1)

NCTAcronymPhaseStatusTitle
NCT01130519HLRCCP2completedA Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Adenomatous Polyposis Coli (1)

NCTAcronymPhaseStatusTitle
NCT01187901FAPESTP2completedA Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

Extrahepatic Bile Duct Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01093222—P2completedSorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Advanced Non-small Cell Lung Cancer (NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT01101334CS-7017P2completedStudy of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Cancer of Head and Neck (1)

NCTAcronymPhaseStatusTitle
NCT01116336—P1completedPhase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

Metastases, Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT01115803—P1terminatedA Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Metastatic Squamous Cell Carcinoma of the Hypopharynx (1)

NCTAcronymPhaseStatusTitle
NCT01064479—P2completedCombination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Advanced Pancreatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT01010945—P1completedErlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Polycythemia Vera (1)

NCTAcronymPhaseStatusTitle
NCT01038856OSI-TAR-766P2terminatedTrial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

Dysplasia (1)

NCTAcronymPhaseStatusTitle
NCT01013831—P1terminatedErlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung

Triple Negative Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00998036—P1completedStudy of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers (1)

NCTAcronymPhaseStatusTitle
NCT00975182—P1completedA Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Primary Sclerosing Cholangitis (1)

NCTAcronymPhaseStatusTitle
NCT00955149PSCP1completedErlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Advanced Malignancies, Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00975767—P1terminatedA Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Recurrent Head and Neck Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00954226—P1completedPhase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Thoracic Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT01024413—P3completedPhase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Head And Neck Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00942734—P2completedTrial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Carcinoma, Hepatocellular (1)

NCTAcronymPhaseStatusTitle
NCT00901901SEARCHP3completedNexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Locally Advanced, Metastatic Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT00848718MK-2206-003P1completedA Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Rash (1)

NCTAcronymPhaseStatusTitle
NCT00473083LUTRAERLP2completedSystemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer

Leptomeningeal Carcinomatosis (1)

NCTAcronymPhaseStatusTitle
NCT00830245—P2terminatedA Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Advanced Malignant Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT00884845—P1completedTrial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Unresectable, Metastatic Biliary Tract Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01149122GEMOXP3completedGemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma

Liver Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00791544—P1/P2terminatedDose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Refractory Solid Tumors (1)

NCTAcronymPhaseStatusTitle
NCT00759928—P1completedPK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Pancreatic Carcinoma Non-resectable (1)

NCTAcronymPhaseStatusTitle
NCT00761345—P1completedStudy of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

Malignant Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT00725634P05538P1completedA Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma

Locally Advanced Non-Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00702975NSCLCP2completedStudy of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00737243—P2completedTreatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Adenomatous Polyp (1)

NCTAcronymPhaseStatusTitle
NCT00754494—P2completedErlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma

Breast Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT00732810—P2completedSCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Advanced Solid Tumor Malignancies (1)

NCTAcronymPhaseStatusTitle
NCT00996515—P1completedA Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Recurrent Bladder Urothelial Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00749892—P2completedErlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Carcinoma, Large Cell (1)

NCTAcronymPhaseStatusTitle
NCT00673049NSCLCP3terminatedTrial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Recurrent Non Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00652340TP2001-201P2completedAPRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer

Nonsquamous Nonsmall Cell Neoplasm of Lung (1)

NCTAcronymPhaseStatusTitle
NCT01161173TEAMN/AcompletedAn Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer

Estrogen Receptor-negative Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00733408—P2completedNab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Metastatic Adenocarcinoma of the Pancreas (1)

NCTAcronymPhaseStatusTitle
NCT00873353XELTAP2completedTrial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients

Stage IV Pancreatic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00617708—P1/P2completedS0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Unresectable Adenocarcinoma of the Esophagus (1)

NCTAcronymPhaseStatusTitle
NCT00591123—P2completedStudy of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

Malignant Disease (1)

NCTAcronymPhaseStatusTitle
NCT00881166SGI-0470-02P1completedSafety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Non Small Cell Lung Cancer (NSCLC) (1)

NCTAcronymPhaseStatusTitle
NCT00637910TAILORP3unknownTarceva Italian Lung Optimization tRial

Lung Cancer, Non-Small Cell (1)

NCTAcronymPhaseStatusTitle
NCT00619424—P1completedA Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

Intraductal Papillary Mucinous Neoplasm of the Pancreas (1)

NCTAcronymPhaseStatusTitle
NCT00482625—P2terminatedErlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Carcinoma, Renal Cell (1)

NCTAcronymPhaseStatusTitle
NCT00522249—P1/P2terminatedStudy of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Metastatic Pancreatic Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00480584—P1completedA Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Esophageal Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT00442507OSI3650P2terminatedErlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. (1)

NCTAcronymPhaseStatusTitle
NCT00447057NSCLCP2completedStudy of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Cancer of the Pharynx (1)

NCTAcronymPhaseStatusTitle
NCT00970502—P1/P2completedErlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Cervical Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00428194—P1withdrawnErlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Adult Brain Tumors (1)

NCTAcronymPhaseStatusTitle
NCT00387894—P2terminatedErlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Oral Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00402779EPOCP3completedErlotinib Prevention of Oral Cancer (EPOC)

Precancerous Conditions (1)

NCTAcronymPhaseStatusTitle
NCT00314262—P1/P2completedPhase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

Squamous Cell Carcinoma of the Head and Neck (SCCHN) (1)

NCTAcronymPhaseStatusTitle
NCT00392665—P2terminatedBevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Adenocarcinoma, Bronchiolo-Alveolar (1)

NCTAcronymPhaseStatusTitle
NCT00384826—P2completedTherapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Thymic Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00369889—P2completedA Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

Kidney Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00425386—P2completedSunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Neoplasm, Unknown Primary (1)

NCTAcronymPhaseStatusTitle
NCT00360360—P2completedPaclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Metastatic Solid Tumor (1)

NCTAcronymPhaseStatusTitle
NCT00611468—P1completedPhase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

Nasopharyngeal Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00603915—P2completedA Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer

Cholangiocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00350753—P2completedAvastin and Tarceva for Upper Gastrointestinal Cancers

Stage IV Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00300586—P3completedIFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

Cholangiocarcinoma of the Extrahepatic Bile Duct (1)

NCTAcronymPhaseStatusTitle
NCT00356889—P2completedBevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

Bronchioloalveolar Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00950365—P2completedPemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Glioblastoma Multiforme (1)

NCTAcronymPhaseStatusTitle
NCT00301418—P1/P2completedOral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

Squamous Cell Carcinoma of the Head and Neck (1)

NCTAcronymPhaseStatusTitle
NCT00442455—P3completedErlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT01515137—P1completedStudy of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

CNS Tumor, Adult (1)

NCTAcronymPhaseStatusTitle
NCT00274833—P2completedRadiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Ovarian Neoplasms (1)

NCTAcronymPhaseStatusTitle
NCT00130520—P2completedBevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Malignant Brain Tumor (1)

NCTAcronymPhaseStatusTitle
NCT00418327—P1completedSafety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Stage IA Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00087269—P2terminatedErlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Adenocarcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00137839—P2completedErlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

Metastatic Malignant Neoplasm in the Brain (1)

NCTAcronymPhaseStatusTitle
NCT00096265—P3terminatedRadiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

Melanoma (1)

NCTAcronymPhaseStatusTitle
NCT00466687—P2completedErlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Clear Cell Renal Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00193258—P1/P2completedBevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Solid Neoplasm (1)

NCTAcronymPhaseStatusTitle
NCT00085553—P1completedTipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

Neoplasms, Unknown Primary (1)

NCTAcronymPhaseStatusTitle
NCT00193622—P2completedBevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Previously Treated Childhood Rhabdomyosarcoma (1)

NCTAcronymPhaseStatusTitle
NCT00077454—P1completedErlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT00137826—P2completedBevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Sarcoma (1)

NCTAcronymPhaseStatusTitle
NCT00068367—P2completedS0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

Advanced Non Small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00072631—P2completedErlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Mucinous Adenocarcinoma of the Colon (1)

NCTAcronymPhaseStatusTitle
NCT00060411—P1completedA Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

Recurrent Renal Cell Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00060307—P2completedErlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

Brenner Tumor (1)

NCTAcronymPhaseStatusTitle
NCT00059787—P2completedErlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) (1)

NCTAcronymPhaseStatusTitle
NCT01116622—P1completedErlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

Recurrent Squamous Cell Carcinoma of the Hypopharynx (1)

NCTAcronymPhaseStatusTitle
NCT00055913—P1/P2completedBevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Breast Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00054132—P2completedErlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity (1)

NCTAcronymPhaseStatusTitle
NCT00049166—P1completedErlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

Recurrent Salivary Gland Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00055770—P1/P2completedErlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

Advanced Malignant Mesothelioma (1)

NCTAcronymPhaseStatusTitle
NCT00039182—P2completedErlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00590902—P2completedPh II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer

Cervical Squamous Cell Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00031993—P2completedErlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Adult Primary Cholangiocellular Carcinoma (1)

NCTAcronymPhaseStatusTitle
NCT00033462—P2completedErlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Endometrial Cancer (1)

NCTAcronymPhaseStatusTitle
NCT00030485—P2completedErlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Psoriasis (1)

NCTAcronymPhaseStatusTitle
NCT01006096—P2withdrawnErlotinib for Treatment of Psoriasis

Pancreatic Cancer, Metastatic (1)

NCTAcronymPhaseStatusTitle
NCT01600807—P1/P2withdrawnOSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Erlotinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
TCL-1NCT02031601P4unknownNon-Small-Cell Lung Cancer250PMID 31200823
REALMENCT01320501P4suspendedNon-small Cell Lung Cancer Metastatic100—
PFSNCT02000531P4completedCarcinoma, Non-Small-Cell Lung45—
NSCLCNCT00949910P4completedNon-Small Cell Lung Cancer6,586PMID 25855621
RELAYNCT02411448P3active not recruitingMetastatic Non-Small Cell Lung Cancer545PMID 29317191
JUNIPERNCT02152631P3active not recruitingNon Small Cell Lung Cancer453PMID 26432508
FLAURANCT02296125P3completedLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer674PMID 35099678
BEVERLYNCT02633189P3unknownNon-squamous Non-small Cell Lung Cancer200PMID 35659580
EGF816NCT03529084P3withdrawnCarcinoma, Non-small Cell Lung0—
ARCTICNCT02352948P3completedNon - Small Cell Lung Cancer NSCLC597PMID 32201234
effectNCT02886195P3unknownEGFR Gene Mutation120PMID 34168480
EPOCNCT00402779P3completedOral Cancer303PMID 26540028
SEARCHNCT00901901P3completedCarcinoma, Hepatocellular732—
BIBW 2992NCT01523587P3completedCarcinoma, Non-Small-Cell Lung795PMID 26156651
SOLARNCT02588261P3terminatedNon-small Cell Lung Cancer (NSCLC)530PMID 31070709
ESSENCENCT01667562P3completedNon-Small Cell Lung Cancer375—
HER3-LungNCT02134015P3terminatedLung Cancer145—
ENTERNCT01887795P3completedMultiple Brain Metastases224PMID 33331923
NSCLCNCT01351415P3completedNon-Squamous Non-Small Cell Lung Cancer485PMID 26828788
NSCLCNCT01328951P3completedNon-Squamous Non-Small Cell Lung Cancer643—
EMPHASISNCT01652469P3completedCarcinoma, Non-Small-Cell Lung81PMID 17909350
FLARENCT02178397P3terminatedNSCLC Patients With EGFR Activating Mutation6—
ARCHER 1009NCT01360554P3completedNon-Small Cell Lung Cancer878PMID 25439691
EGFRNCT01887886P3completedNon-Squamous Non-Small Cell Lung Cancer10—
MARVELNCT00738881P3terminatedRecurrent Non-Small Cell Lung Carcinoma23—
ESCC-307PLAHNCT01752205P3unknownEsophageal Squamous Carcinoma120—
ATLASNCT00257608P3completedNon-Small Cell Lung Cancer1,145PMID 24101054
RADIANTNCT00373425P3completedNon-small Cell Lung Cancer1,252PMID 26324372
NSCLCNCT00153803P3completedCarcinoma, Non-Small-Cell Lung245—
CURRENTSNCT01183858P3completedNon-Small Cell Lung Cancer315—
ACT2NCT01229813P3completedColorectal Cancer233PMID 26483047
NSCLCNCT01158170P3unknownNon-small Cell Lung Cancer200—
TAILORNCT00637910P3unknownNon Small Cell Lung Cancer (NSCLC)850PMID 26209642
EURTACNCT00446225P3completedNon-Small Cell Lung Cancer174PMID 22285168
ACTNCT00598156P3completedMetastatic Colorectal Cancer249PMID 23788755
ML20981NCT00874419P3completedNon-small Cell Lung Cancer165PMID 26141208
GEMOXNCT01149122P3completedUnresectable, Metastatic Biliary Tract Carcinoma266PMID 22192731
TORCHNCT00349219P3completedAdvanced Non-Small Cell Lung Cancer760PMID 22778317
NSCLCNCT00556322P3completedNon-Small Cell Lung Cancer424PMID 22277837
NSCLCNCT00673049P3terminatedCarcinoma, Large Cell583PMID 25395283
ATTENTIONNCT01377376P3terminatedNon-small-cell Lung Cancer0PMID 26153496
NSCLCNCT00556712P3completedNon-Small Cell Lung Cancer889PMID 20493771
NSCLCNCT00440414P3completedNon Small Cell Lung Cancer320—
TOPICALNCT00275132P3completedLung Cancer670—
NSCLCNCT00091663P3completedLung Cancer5,000PMID 18438878
DREAMNCT00265824P3completedColorectal Cancer700PMID 26474518
ECHO-BNCT04172779P2not yet recruitingCirrhosis, Liver60—
ProTargetNCT04341181P2recruitingCancer300PMID 36814246
DRUPNCT02925234P2recruitingCancer1,550PMID 37424386
EGFRNCT00977470P2active not recruitingNon-small Cell Lung Cancer76PMID 25759424
CAPTURNCT03297606P2recruitingLymphoma, Non-Hodgkin720—
EGFRNCT05442060P2recruitingNon-small Cell Lung Cancer60—
BRISKNCT05904457P2unknownSolid Tumors32—
BaliseNCT01897480P2completedCarcinoma, Non-Small-Cell Lung168—
ANSWERNCT04455594P2unknownNon-Small Cell Lung Cancer Stage IIIA168—
ROMENCT04591431P2unknownBreast Cancer400PMID 41963505
CUPISCONCT03498521P2completedCancer of Unknown Primary Site529PMID 39096924
BTCNCT03110484P2unknownBiliary Tract Cancer44—
BLISSNCT05081674P2completedLung Neoplasm154—
AvaTaNCT03126799P2unknownEGFR Positive Non-small Cell Lung Cancer128—
HLRCCNCT01130519P2completedHLRCC83PMID 40532152
HCCNCT01180959P2completedLiver Cancer45PMID 26929648
ThoRaTNCT02714530P2terminatedCancer118PMID 39148905
LADIENCT01556191P2completedStage IV Lung Cancer379PMID 32144133
BRILLIANTNCT02655536P2unknownCarcinoma, Non-Small-Cell Lung109PMID 33067126
S0635NCT00436332P2completedLung Cancer84—
NVALT10NCT00835471P2completedCarcinoma, Non-Small-Cell Lung195PMID 31733490
EGFRNCT01573702P2completedNon Small Cell Lung Cancer32—
TARCEVANCT00313560P2completedPancreatic Cancer48PMID 23773391
RadErNCT01518621P2terminatedCancer25—
BIOMEDENCT02233049P2unknownDiffuse Intrinsic Pontine Glioma250PMID 42032072
BELIEFNCT01562028P2completedLung Cancer109PMID 28408243
NSCLCNCT00563784P2completedNon-Small Cell Lung Cancer68PMID 25968826
HS-110NCT02117024P2terminatedNon Small Cell Lung Cancer66—
NSCLCNCT00411632P2completedLung Cancer37PMID 23442309
ML22774NCT01729481P2unknownMetastatic Pancreatic Adenocarcinoma150PMID 37794220
MBCNCT00570258P2terminatedMetastatic Breast Cancer27—
ROLENCT01796288P2unknownNon Small Cell Lung Cancer, Oligometastatic200—
EVENTNCT01857271P2terminatedStage IIIA Non-Small Cell Lung Cancer3—
Gem-oxNCT00832637P2terminatedHepatocellular Carcinoma33—
FOCALNCT02318368P2terminatedNon-small Cell Lung Cancer10—
TRIGGERNCT01378962P2completedNon-Squamous Non-Small Cell Lung Cancer50—
GEMCAD1003NCT01389440P2completedPancreatic Adenocarcinoma24PMID 30225601
INNOVATENCT02095782P2terminatedNon-small-cell Lung Cancer10—
SHIVANCT01771458P2completedReccurent/Metastatic Solid Tumor Disease742PMID 27993804
S0709NCT00661193P2completedLung Cancer59—
EGFRNCT01310036P2completedNon-Squamous Non-Small Cell Lung Cancer208PMID 26720423
ML25444NCT01217619P2completedNon Small Cell Lung Cancer25PMID 31885349
ARQ 197NCT01395758P2completedMetastatic Non-Small Cell Lung Cancer96—
GATE 1NCT01204372P2completedMetastatic Pancreatic Adenocarcinoma63PMID 33405269
DIPGNCT01182350P2terminatedDiffuse Intrinsic Pontine Glioma53PMID 29741745
TRACTSNCT01763385P2unknownNon-small-cell Lung Cancer210—
MIMEBNCT01047059P2completedNon-Small-Cell Lung Carcinoma40—
EGFRNCT02066038P2unknownLung, Carcinoma60—
ChimeNCT01900652P2completedCarcinoma, Non-Small-Cell Lung111—
SCCNCT01059305P2terminatedSkin Cancer10—
SCCANCT00304278P2completedHead and Neck Cancer21—
NSCLCNCT01229150P2completedNon Small Cell Lung Carcinoma89PMID 26802155
EGFRNCT02355431P2withdrawnSolid Tumors and Hematologic Malignancy0—
BIOTECNCT01153984P2completedCarcinoma，Non-Small-Cell Lung23—
GECANCT01303029P2completedMetastatic Pancreatic Cancer120PMID 28222309
UAB0718NCT00570232P2completedHead and Neck Cancer31—
NSCLCNCT01221077P2completedNSCLC88—
TALISMANNCT01204697P2completedNon-Squamous Non-Small Cell Lung Cancer74—
FAPESTNCT01187901P2completedAdenomatous Polyposis Coli92PMID 30012100
GEMNCT01210911P2completedLocally Advanced Pancreatic Cancer120PMID 26067687
GEMOX-TNCT01505413P2completedPancreatic Cancer33—
OSI-TAR-766NCT01038856P2terminatedPolycythemia Vera5—
TARSEQNCT01350817P2completedNon Small Cell Lung Cancer156PMID 25082565
S0636NCT00445848P2completedLung Cancer89—
CTANCT00520013P2completedOvarian Cancer60—
LUTRAERLNCT00473083P2completedRash150PMID 26573073
NSCLC EGFR TKINCT01955421P2unknownAdvanced Stage Non Small Cell Lung Cancer224PMID 33244458
NSCLCNCT00702975P2completedLocally Advanced Non-Small Cell Lung Cancer35—
N2NCT00600587P2completedCarcinoma, Non-Small-Cell Lung24PMID 25981169
GESNCT00696696P2completedPancreatic Cancer45PMID 10655437
CS-7017NCT01101334P2completedAdvanced Non-small Cell Lung Cancer (NSCLC)90—
RT0901NCT01091376P2unknownNon-small Cell Lung Cancer75—
RTNCT00983307P2completedCarcinoma, Non-small-cell Lung17—
PEARLNCT00391248P2completedNon-small Cell Lung Cancer40—
PETEYNCT01032070P2terminatedRecurrent or Refractory Pediatric Ependymoma25—
NSCLCNCT01996332P2completedNon-Small Cell Lung Cancer1,805—
RAD0503NCT00369512P2completedCancer15PMID 23182701
MDSNCT00977548P2completedMyelodysplastic Syndrome39—
OncologyNCT02036359P2unknownNon-small Cell Lung Cancer(NSCLC)76—
INNOVATIONSNCT00536640P2completedCarcinoma, Non-Small-Cell Lung224PMID 25792638
PENGUINNCT00855894P2completedNon-Small Cell Lung Cancer41PMID 24457379
TP2001-201NCT00652340P2completedRecurrent Non Small Cell Lung Cancer120PMID 24736085
SELECTNCT00462995P2completedNon Small Cell Lung Cancer25PMID 12860940
MK-0646NCT00654420P2completedCarcinoma, Non-small-cell Lung95PMID 25414803
SUN1058NCT00265317P2completedCarcinoma, Non-Small-Cell Lung162PMID 23788751
ECONNCT00577707P2completedNon Small Cell Lung Cancer9—
NSCLCNCT00777309P2completedNon Small Cell Lung Cancer167—
NSCLCNCT00447057P2completedHistological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.204—
NSCLCNCT00553800P2completedCarcinoma, Non-Small-Cell Lung32—
DuxNCT00784667P2unknownMetastatic Colorectal Cancer50—
NSCLCNCT00908336P2unknownNon-Small Cell Lung Cancer70—
TACTICNCT00554775P2terminatedLung Cancer80—
XELTANCT00873353P2completedMetastatic Adenocarcinoma of the Pancreas32—
NSCLCNCT00452075P2terminatedNon Small Cell Lung Cancer24—
DOPERLONCT00783471P2terminatedAdvanced Non-Small Cell Lung Cancer51—
NSCLCNCT00760929P2terminatedNon-Squamous Non-Small Cell Lung Cancer171PMID 22025157
NSCLCNCT00988169P2terminatedLung Cancer6—
MGNCT00671970P2completedGlioblastoma57PMID 20716591
NSCLCNCT00773383P2terminatedNon-Small Cell Lung Cancer35—
ERLOPETNCT00568841P2unknownCarcinoma, Non-Small-Cell Lung40PMID 25226426
MERITNCT02774278P2completedNon-Squamous Non-Small Cell Lung Cancer264—
EGFRNCT00570375P2withdrawnMyelodysplastic Syndrome0—
MATERNCT00642473P2completedNon-Squamous Non-Small Cell Lung Cancer34—
NSCLCNCT00370383P2completedLung Cancer100—
NSCLCNCT00600015P2completedNon-Small Cell Lung Cancer166PMID 21576636
OSI3650NCT00442507P2terminatedEsophageal Neoplasms6PMID 16177283
PSANCT00148772P2completedProstate Cancer29—
NSCLCNCT00085839P2completedNon-Small Cell Lung Cancer103PMID 18281658
TIENCT00678964P2unknownNon-Small Cell Lung Cancer260—
S0341NCT00087412P2completedAdenocarcinoma of the Lung65—

Terminated and withdrawn Erlotinib trials (140)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

  • NCT05827614terminatedStudy of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
  • NCT06161558withdrawnErlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
  • NCT02991651terminatedStudy of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
  • NCT03529084withdrawnPhase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
  • NCT02714530terminatedThoracal Radiotherapy and Tarceva
  • NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
  • NCT02795884withdrawnAdjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
  • NCT04165031terminatedA Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
  • NCT01455389terminatedTUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
  • NCT02689336withdrawnErlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
  • NCT03213626terminatedCabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
  • NCT02770014terminatedRapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
  • NCT02775006terminatedDocetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
  • NCT02556593terminatedIMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
  • NCT02080078terminatedA Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
  • NCT01518621terminatedWhole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer
  • NCT02468661terminatedA Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
  • NCT03460678terminatedRandomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
  • NCT01822496terminatedErlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
  • NCT02117024terminatedA Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
  • NCT01471964terminatedStudy to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
  • NCT02169284terminatedErlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
  • NCT02342353terminatedPacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
  • NCT01962896terminatedA Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
  • NCT01376310terminatedGSK1120212 Rollover Study
  • NCT01190241terminatedTargeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study
  • NCT00570258terminatedRandomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
  • NCT02588261terminatedA Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
  • NCT01857271terminatedErlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer
  • NCT02186301terminatedTIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
  • NCT00573989terminatedIntensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
  • NCT00832637terminatedGemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
  • NCT02206763terminatedErlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • NCT02318368terminatedA Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
  • NCT02095782terminatedChemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation
  • NCT02034097withdrawnA Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
  • NCT02134015terminatedStudy of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
  • NCT02926638terminatedLung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
  • NCT02495233terminatedA Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
  • NCT01320501suspendedExperience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  • NCT00843531terminatedRAD001 and Erlotinib in Patients With Neuroendocrine Tumors
  • NCT01182350terminatedMolecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
  • NCT01284335terminatedA Safety Study in Participants With Advanced Solid Tumors
  • NCT01728181withdrawnA Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
  • NCT01059305terminatedPhase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
  • NCT02277457withdrawnPersonalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
  • NCT02355431withdrawnItacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
  • NCT02134886terminatedErlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
  • NCT02178397terminatedA Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
  • NCT01193881terminatedRO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
  • NCT01928160withdrawnPemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
  • NCT01515969terminatedPhase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
  • NCT00738881terminatedPemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
  • NCT01990261terminatedA Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment
  • NCT00975767terminatedA Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
  • NCT01110876terminatedPhase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
  • NCT02044601withdrawnBiomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
  • NCT01038856terminatedTrial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
  • NCT00392665terminatedBevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
  • NCT00976677terminatedCarboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
  • NCT01465815withdrawnPhase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
  • NCT00482625terminatedErlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
  • NCT01487174terminatedKD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
  • NCT01013831terminatedErlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung
  • NCT01103375terminatedErlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
  • NCT01432119withdrawnPhase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
  • NCT01009203terminatedTemsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
  • NCT01003938terminatedTopotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
  • NCT00811993terminatedA Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
  • NCT01244191terminatedTivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
  • NCT01026844terminatedHydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)
  • NCT01032070terminatedErlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
  • NCT01192815terminatedErlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
  • NCT01247922terminatedSingle-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
  • NCT00391586terminatedErlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
  • NCT01600807withdrawnOSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
  • NCT00673049terminatedTrial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
  • NCT00592007terminatedStudy Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
  • NCT00096265terminatedRadiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
  • NCT01189435terminatedErlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
  • NCT00448240terminatedErlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
  • NCT00503971terminatedPhase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
  • NCT00642746terminatedErlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
  • NCT00336700terminatedA Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
  • NCT00940875terminatedA Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
  • NCT01377376terminatedA Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
  • NCT01205685terminatedEndocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
  • NCT00841035terminated7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
  • NCT00830245terminatedA Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
  • NCT01188707terminatedA Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
  • NCT01115803terminatedA Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
  • NCT00954512terminatedStudy of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
  • NCT01332279withdrawnEverolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
  • NCT00539617terminatedChemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
  • NCT00597597terminatedPhase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
  • NCT01108458terminatedA Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
  • NCT00564720terminatedGemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
  • NCT00281021terminatedSecond Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
  • NCT00554775terminatedWBRT & Erlotinib in Advanced NSCLC and Brain Metastases
  • NCT00749567terminatedCombination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer
  • NCT00470535terminatedErlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
  • NCT00728000withdrawnPhase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
  • NCT00532441terminatedErlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
  • NCT00452075terminatedErlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
  • NCT00783471terminatedDocetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)
  • NCT00750698terminatedA Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
  • NCT00760929terminatedA Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
  • NCT00988169terminatedErlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
  • NCT00947167terminatedA Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
  • NCT00503841terminatedErlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
  • NCT00276744terminatedIndividualized Drug Treatment for Treating Patients With Pancreatic Cancer
  • NCT00640978terminatedErlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
  • NCT00996502terminatedStudy of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
  • NCT00773383terminatedA Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
  • NCT01013506withdrawnPhase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
  • NCT00750555terminatedMaintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
  • NCT00412217terminatedA Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
  • NCT00791544terminatedDose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
  • NCT01006096withdrawnErlotinib for Treatment of Psoriasis
  • NCT00738335withdrawnStereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
  • NCT00570375withdrawnThe Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome
  • NCT00642733terminatedA Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
  • NCT00387894terminatedErlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
  • NCT00442507terminatedErlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
  • NCT00385398withdrawnQOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
  • NCT00611715terminatedPh II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
  • NCT00766636terminatedPreoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
  • NCT00351039terminatedPhase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
  • NCT00522249terminatedStudy of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
  • NCT00522938terminatedClinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
  • NCT00428194withdrawnErlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
  • NCT00227032terminatedErlotinib in Treating Patients With Progressive Glioblastoma Multiforme
  • NCT00251589terminatedA Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
  • NCT00536770suspendedA Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
  • NCT00283634terminatedA Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
  • NCT00459901terminatedStudy of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer
  • NCT00293436withdrawnCelecoxib and Erlotinib in Treating Patients With Liver Cancer
  • NCT00087269terminatedErlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
  • NCT00047333terminatedErlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
  • NCT00042835terminatedErlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

All Erlotinib trials (698)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT06545695Epidermal Growth Factor Receptor Inhibition for KeratinopathiesP1/P2not yet recruiting44Northwestern UniversityJul 2027
NCT04172779ECHO-BErlotinib for Hepatocellular Carcinoma ChemopreventionP2not yet recruiting60University of Texas Southwestern Medical CenterDec 2026
NCT04341181ProTargetProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingP2recruiting300Ulrik LassenAug 2020
NCT07418177Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMDP1/P2not yet recruiting9The First Affiliated Hospital with Nanjing Medical UniversityFeb 2026
NCT03137771Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerP2active not recruiting218NRG OncologyApr 2017
NCT06997068Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationP2recruiting25Mayo ClinicJul 2025
NCT04981509Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerP2recruiting65National Cancer Institute (NCI)Jun 2022
NCT04449874A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationP1active not recruiting498Genentech, Inc.Jul 2020
NCT02925234DRUPThe Drug Rediscovery Protocol (DRUP Trial)P2recruiting1,550The Netherlands Cancer InstituteAug 2016
NCT00977470EGFRErlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) MutationsP2active not recruiting76Massachusetts General HospitalOct 2009
NCT06483555PANGEABasal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelP1/P2recruiting104UNC Lineberger Comprehensive Cancer CenterFeb 2025
NCT05525858KOSMOSIIKPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II—recruiting1,000Seoul National University Bundang HospitalSep 2022
NCT01708954Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerP2active not recruiting125National Cancer Institute (NCI)Feb 2013
NCT01660971Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryP1active not recruiting19National Cancer Institute (NCI)Jul 2012
NCT00878163GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryP1active not recruiting55National Cancer Institute (NCI)Mar 2009
NCT02193282Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)P3active not recruiting390National Cancer Institute (NCI)Feb 2015
NCT03297606CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)P2recruiting720Canadian Cancer Trials GroupMar 2018
NCT02411448RELAYA Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)P3active not recruiting545Eli Lilly and CompanyMay 2015
NCT02152631JUNIPERA Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerP3active not recruiting453Eli Lilly and CompanyOct 2014
NCT02194738Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)N/Aactive not recruiting8,300National Cancer Institute (NCI)Sep 2014
NCT02099058PKA Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsP1active not recruiting237AbbVieJan 2014
NCT06071013Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsP1/P2recruiting20China Medical University HospitalFeb 2024
NCT00045201Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid TumorsP1active not recruiting60National Cancer Institute (NCI)Jun 2002
NCT05442060EGFRTo Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerP2recruiting60OBI Pharma, IncJul 2022
NCT05827614POTENTIATEStudy of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsP1terminated85Boundless Bio, Inc.Mar 2023
NCT05904457BRISKA Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerP2unknown32Asan Medical CenterJan 2023
NCT01897480BaliseA Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsP2completed168Eli Lilly and CompanyAug 2013
NCT00600496ARRY-142886A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)P1completed140AstraZenecaDec 2007
NCT02098954Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung CancersP2unknown40Hunan Province Tumor HospitalJul 2014
NCT03647592Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer—unknown30Hunan Province Tumor HospitalJun 2018
NCT02296125FLAURAAZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerP3completed674AstraZenecaDec 2014
NCT06675695NCT02296125Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases—completed4,864Brigham and Women's HospitalOct 2024
NCT04455594ANSWERAlmonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCP2unknown168The First Affiliated Hospital of Guangzhou Medical UniversityOct 2020
NCT01013649Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryP3completed546National Cancer Institute (NCI)Apr 2010
NCT06161558Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid TumorsP1withdrawn0National Cancer Institute (NCI)Jul 2025
NCT04591431ROMEThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyP2unknown400Fondazione per la Medicina PersonalizzataOct 2020
NCT02991651Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCP1terminated12Io TherapeuticsDec 2016
NCT00954226Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck CancerP1completed48M.D. Anderson Cancer CenterAug 2009
NCT01927744Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical ResectionP2completed55M.D. Anderson Cancer CenterDec 2013
NCT03498521CUPISCOA Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteP2completed529Hoffmann-La RocheJul 2018
NCT02633189BEVERLYStudy Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerP3unknown200National Cancer Institute, NaplesApr 2016
NCT01306045Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesP2completed647National Cancer Institute (NCI)Feb 2011
NCT03110484BTCPemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective StudyP2unknown44Samsung Medical CenterJul 2021
NCT03529084EGF816Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating MutationsP3withdrawn0Novartis PharmaceuticalsJul 2018
NCT00254384Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following SurgeryP1completed50M.D. Anderson Cancer CenterOct 2005
NCT05834348DELINORA Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.—completed5,279PfizerJun 2023
NCT04575415BELLABevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study—unknown272Guangdong Association of Clinical TrialsOct 2020
NCT03239015Efficacy and Safety of Precision Therapy in Refractory TumorP2unknown300Baodong QinJan 2017
NCT02638428Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyP2unknown90Samsung Medical CenterDec 2015
NCT07271446PB101An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung CancerP1completed8Precision Biotech Taiwan Corp.Sep 2018
NCT02352948ARCTICA Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerP3completed597AstraZenecaJan 2015
NCT05081674BLISSBrazilian Lung Immunotherapy StudyP2completed154Hospital Israelita Albert EinsteinJan 2020
NCT03126799AvaTaA Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)P2unknown128National Cancer Center, KoreaNov 2016
NCT02091141My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsP2completed673Genentech, Inc.Apr 2014
NCT01407822EMERGINGErlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung CancerP2/P3unknown72Guangdong Association of Clinical TrialsDec 2011
NCT02942095Study of Ixazomib and Erlotinib in Solid TumorsP1completed9M.D. Anderson Cancer CenterMar 2017
NCT03720873EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLCP2unknown90Fujian Cancer HospitalOct 2018
NCT03653546BMFirst Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesP2/P3completed492Alpha Biopharma (Jiangsu) Co., Ltd.Oct 2018
NCT01470716Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR MutationsP2unknown26National Cancer Center, KoreaJan 2012
NCT01130519HLRCCA Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerP2completed83National Cancer Institute (NCI)May 2010
NCT02154490Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer—completed1,864SWOG Cancer Research NetworkJul 2014
NCT02273362Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the LiverP1/P2completed25National Cancer Institute (NCI)Nov 2014
NCT02239952HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)N/Aunknown15Amsterdam UMC, location VUmcNov 2014
NCT02039674MK-3475A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)P1/P2completed267Merck Sharp & Dohme LLCFeb 2014
NCT02961374Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon CancerP2completed46National Cancer Institute (NCI)Oct 2017
NCT02535338Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerP1/P2completed11National Cancer Institute (NCI)Apr 2016
NCT02424617A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerP1/P2completed40BerGenBio ASAApr 2015
NCT01454102BMS-936558Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)P1completed472Bristol-Myers SquibbDec 2011
NCT04179890UpSwinGThe Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib—completed462Boehringer IngelheimDec 2019
NCT01180959HCCErlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line TherapyP2completed45M.D. Anderson Cancer CenterApr 2011
NCT01197170Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome ResistanceP1completed277M.D. Anderson Cancer CenterSep 2010
NCT03628521First-line Combination Treatment Based on AnlotinibP1unknown80Shanghai Chest HospitalJul 2018
NCT02714530ThoRaTThoracal Radiotherapy and TarcevaP2terminated118Oslo University HospitalApr 2014
NCT03076164A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibP1/P2completed24Memorial Sloan Kettering Cancer CenterMar 2017
NCT03878524SMMARTSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialP1terminated2OHSU Knight Cancer InstituteApr 2020
NCT02795884Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR MutationP3withdrawn0Yonsei UniversityJun 2016
NCT01248247BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung CancerP2completed334M.D. Anderson Cancer CenterJun 2011
NCT01064479Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckP2completed123M.D. Anderson Cancer CenterFeb 2010
NCT01683175Erlotinib in Post Radical Operation NSCLC Patients With EGFR MutationP2unknown94Tianjin Medical University Cancer Institute and HospitalAug 2012
NCT04165031A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C MutationP1/P2terminated5Eli Lilly and CompanyNov 2019
NCT01455389TUSC2-nanoparticles and Erlotinib in Stage IV Lung CancerP1/P2terminated25Genprex, Inc.Feb 2014
NCT02154737Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic CancerP1completed24Tony Reid, M.D., Ph.D.Jul 2013
NCT00769483MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic CancerP1/P2completed81M.D. Anderson Cancer CenterNov 2008
NCT01911507INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung CancerP1completed35University of California, DavisAug 2013
NCT01532089Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsP2completed88Academic and Community Cancer Research UnitedMar 2012
NCT03074864TRENDTargeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLCP2/P3unknown90Guangdong Provincial People's HospitalFeb 2017
NCT01556191LADIELung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRP2completed379Intergroupe Francophone de Cancerologie ThoraciqueMay 2012
NCT02689336Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid TumorsP2withdrawn0Washington University School of MedicineAug 2016
NCT00543504Bevacizumab in Multiple Phase I CombinationsP1completed343M.D. Anderson Cancer CenterOct 2007
NCT02574078CheckMate370A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)P1/P2completed341Bristol-Myers SquibbNov 2015
NCT02759614Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR MutationsP3completed311Guangdong Association of Clinical TrialsApr 2016
NCT02013219NSCLCA Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)P1completed52Hoffmann-La RocheApr 2014
NCT02655536BRILLIANTBevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II TrialP2unknown109National Taiwan University HospitalAug 2017
NCT00130728A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung CancerP3completed636Genentech, Inc.Jun 2005
NCT00871923Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung CancerP2completed44M.D. Anderson Cancer CenterMar 2009
NCT01636908ICKDetermination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.N/Acompleted43Amsterdam UMC, location VUmcAug 2011
NCT00749892Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial CancerP2completed34M.D. Anderson Cancer CenterJun 2008
NCT03213626Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic AdenocarcinomaP2terminated7Patrick Joseph Loehrer Sr.Oct 2017
NCT03123484β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLCP2unknown80China Medical University, ChinaApr 2017
NCT03050411Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung CancerP1unknown30Peking University Third HospitalMay 2016
NCT02737228Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic CancerP1/P2unknown24CrystalGenomics, Inc.Mar 2016
NCT01859026A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationP1completed43H. Lee Moffitt Cancer Center and Research InstituteDec 2013
NCT00436332S0635S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar CarcinomaP2completed84SWOG Cancer Research NetworkJul 2007
NCT02886195effectEGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLCP3unknown120Fujian Cancer HospitalJul 2016
NCT00137839Erlotinib in Women With Previously Untreated Adenocarcinoma of the LungP2completed84Pasi A. Janne, MD, PhDNov 2004
NCT03403049Carbon Ion Radiation Therapy for Locally Advanced Pancreatic CancerP1completed14Montefiore Medical CenterApr 2016
NCT00835471NVALT102nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)P2completed195Dutch Society of Physicians for Pulmonology and TuberculosisMar 2009
NCT02770014Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung CancerP2terminated43Dana-Farber Cancer InstituteJun 2016
NCT00733746Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryP2completed123Alliance for Clinical Trials in OncologyApr 2009
NCT01198028Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell CarcinomaP2completed42M.D. Anderson Cancer CenterMar 2011
NCT02775006Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaP3terminated45The Netherlands Cancer InstituteOct 2016
NCT02556593IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain MetastasesP2terminated12Sun Yat-sen UniversitySep 2015
NCT02080078A Phase I Dose Escalation Study of Erlotinib in Combination With TheophyllineP1terminated15AHS Cancer Control AlbertaSep 2014
NCT01573702EGFRStereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)P2completed32UNC Lineberger Comprehensive Cancer CenterDec 2012
NCT00313560TARCEVAChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)P2completed48Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 2006
NCT02399566Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung AdenocarcinomaP4unknown300Hunan Province Tumor HospitalMay 2015
NCT02723578Pemetrexed and Erlotinib for Metastatic Colorectal CancerP2completed50Yonsei UniversityDec 2015
NCT02140333Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLCP3unknown220The First Affiliated Hospital of Guangzhou Medical UniversityAug 2013
NCT01257594EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant GliomasP1completed22Andrew B Lassman, MDJan 2011
NCT01518621RadErWhole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung CancerP2terminated25Oslo University HospitalMay 2012
NCT02468661A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationP1terminated23Novartis PharmaceuticalsSep 2015
NCT03460678Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.P4terminated9Hikma Pharmaceuticals LLCFeb 2018
NCT01967095Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung CancerP1completed53Memorial Sloan Kettering Cancer CenterOct 2013
NCT02233049BIOMEDEBiological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) EradicationP2unknown250Gustave Roussy, Cancer Campus, Grand ParisOct 2014
NCT01562028BELIEFBELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)P2completed109ETOP IBCSG Partners FoundationJun 2012
NCT01664897Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaP2completed29M.D. Anderson Cancer CenterMay 2013
NCT00100854Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerP2completed108Translational Oncology Research InternationalOct 2004
NCT00720356Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaP2completed115Northwestern UniversityJul 2009
NCT02488330An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored StudyP3completed12Hoffmann-La RocheAug 2015
NCT01822496Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung CancerP2terminated59National Cancer Institute (NCI)Nov 2013
NCT00402779EPOCErlotinib Prevention of Oral Cancer (EPOC)P3completed303M.D. Anderson Cancer CenterNov 2006
NCT01116336Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & NeckP1completed25Emory UniversityMar 2010
NCT00563784NSCLCTARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)P2completed68M.D. Anderson Cancer CenterNov 2007
NCT00901901SEARCHNexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular CarcinomaP3completed732BayerMay 2009
NCT00085553Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid TumorsP1completed29National Cancer Institute (NCI)May 2004
NCT02117024HS-110A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung CancerP2terminated66Heat BiologicsJul 2014
NCT01471964Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung CancerP1/P2terminated22Fox Chase Cancer CenterOct 2011
NCT02169284Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing SurgeryP2terminated50National Cancer Institute (NCI)Oct 2014
NCT01866410Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung CancerP2completed37National Cancer Institute (NCI)May 2013
NCT01998126Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerP1completed14University of UtahDec 2013
NCT00411632NSCLCBATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)P2completed37M.D. Anderson Cancer CenterNov 2006
NCT02342353EGFRPacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)P1terminated8Washington University School of MedicineMay 2015
NCT01962896A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell TumorsP2terminated4Theodore LaetschJan 2014
NCT01376310GSK1120212 Rollover StudyP2terminated159Novartis PharmaceuticalsNov 2010
NCT02031601TCL-1Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung CancerP4unknown250Qilu Hospital of Shandong UniversityJan 2014
NCT02013089GITICA Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC StudyN/Aunknown50Sun Yat-sen UniversityDec 2013
NCT02037997Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLCP2unknown80Fudan UniversityDec 2013
NCT02015728SEEDSelecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain TumorsN/Aunknown20Seattle Children's HospitalDec 2013
NCT01965275High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIsP2unknown20Anhui Medical UniversityOct 2013
NCT01729481ML22774Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic CancerP2unknown150Ludwig-Maximilians - University of MunichJul 2012
NCT02738983RT Plus EGFR-TKI for Wild-type NSCLCP2unknown22Hangzhou Cancer HospitalJan 2012
NCT01190241TSAPTargeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory StudyN/Aterminated45Amsterdam UMC, location VUmcAug 2010
NCT00567359Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFRP2completed100Massachusetts General HospitalDec 2007
NCT00491816Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast CancerP2unknown32University of Kansas Medical CenterJul 2007
NCT00570258MBCRandomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal TherapyP2terminated27University of ArkansasSep 2006
NCT01523587BIBW 2992LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyP3completed795Boehringer IngelheimMar 2012
NCT02588261SOLARA Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsP3terminated530Astellas Pharma Global Development, Inc.Feb 2016
NCT02450591Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR MutationsN/Acompleted4Memorial Sloan Kettering Cancer CenterMay 2015
NCT01487265Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibP2completed37SCRI Development Innovations, LLCMar 2014
NCT00126581Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung CancerP2completed188National Cancer Institute (NCI)Aug 2005
NCT00950365Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung CancerP2completed79Albert Einstein College of MedicineApr 2006
NCT02155465Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibP1/P2completed22Memorial Sloan Kettering Cancer CenterJun 2014
NCT01796288ROLEThe Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line TreatmentP2unknown200Wu Jieping Medical FoundationOct 2012
NCT01801111RO5424802A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentP1/P2completed138Hoffmann-La RocheJun 2013
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerP2completed24Fox Chase Cancer CenterFeb 2011
NCT01260181A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsP2completed30Hoffmann-La RocheMar 2011
NCT00733408Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerP2completed59University of WashingtonApr 2008
NCT01667562ESSENCEA Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerP3completed375Hoffmann-La RocheJan 2012
NCT01857271EVENTErlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung CancerP2terminated3Albert Einstein College of MedicineNov 2013
NCT01410214Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR MutationsP2unknown80Chinese Lung Cancer Surgical GroupMay 2011
NCT00547105Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerP2completed24University of Texas Southwestern Medical CenterJun 2007
NCT02186301EGFRTIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed TherapyP2/P3terminated100Clovis Oncology, Inc.Nov 2014
NCT00553462Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryP2completed78Alliance for Clinical Trials in OncologyMar 2008
NCT02889692Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary AdenocarcinomaP3completed23Shanghai University of Traditional Chinese MedicineMar 2013
NCT02064491Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLCP2completed18Finnish Lung Cancer GroupFeb 2014
NCT01688973Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by SurgeryP2completed55National Cancer Institute (NCI)Aug 2012
NCT01472016Study of ABT-700 in Subjects With Advanced Solid TumorsP1completed74AbbVie (prior sponsor, Abbott)Oct 2011
NCT00573989Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck CancerP1/P2terminated27Wake Forest University Health SciencesMar 2008
NCT00832637Gem-oxGemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree CancersP2terminated33New Mexico Cancer Research AllianceAug 2007
NCT01592383Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal MesotheliomaP2completed2University of ChicagoJun 2012
NCT00881751Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver CancerP2completed95Medical University of South CarolinaMar 2009
NCT02206763EGFRErlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)P1terminated11Sierra Oncology LLC - a GSK companyOct 2014
NCT02318368FOCALA Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive LabelP2terminated10AVEO Pharmaceuticals, Inc.Nov 2014
NCT01378962TRIGGERA Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)P2completed50Hoffmann-La RocheMar 2011
NCT00997334Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLCP2completed60David M. Jackman, MDFeb 2010
NCT01389440GEMCAD1003Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic CancerP2completed24Grupo Espanol Multidisciplinario del Cancer DigestivoMay 2011
NCT02095782INNOVATEChemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor MutationP2terminated10Guangdong Association of Clinical TrialsMar 2014
NCT01104155Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung CancerP2completed123Eisai Inc.Feb 2010
NCT02321293CURCUMINA Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLCP1unknown20Lady Davis InstituteAug 2015
NCT02034097A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung CancerP2withdrawn0GlaxoSmithKlineApr 2014
NCT01771458SHIVAA Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory CancerP2completed742Institut CurieOct 2012
NCT01693419S-1, Gemcitabine and Erlotinib for Advanced Pancreatic CancerP2completed37Hallym University Medical CenterAug 2011
NCT00661193S0709S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung CancerP2completed59SWOG Cancer Research NetworkDec 2008
NCT00499655Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerP2completed107City of Hope Medical CenterNov 2007
NCT01310036EGFRA Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) MutationsP2completed208Hoffmann-La RocheApr 2011
NCT02057380A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib TrialP2completed13Astellas Pharma Global Development, Inc.Apr 2014
NCT01174563A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line TherapyP2completed60Hoffmann-La RocheMay 2011
NCT00400374Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2P1completed10Emory UniversityAug 2007
NCT00364351Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior ChemotherapyP3completed1,574Genzyme, a Sanofi CompanyAug 2006
NCT02134015HER3-LungStudy of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)P3terminated145Daiichi SankyoMar 2014
NCT01839955Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung CancerP1completed12Neelesh Sharma MD PhDSep 2013
NCT00987766Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary CancerP1completed28Vanderbilt-Ingram Cancer CenterNov 2009
NCT01217619ML25444Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.P2completed25Baohui HanMar 2011
NCT01287546A Study of LY2875358 in Participants With Advanced CancerP1completed117Eli Lilly and CompanyApr 2010
NCT02926638Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesP2/P3terminated9SWOG Cancer Research NetworkJun 2014
NCT02495233EGFRA Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)P1/P2terminated10Astellas Pharma Global Development, Inc.Sep 2015
NCT01887795ENTERPhase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised StudyP3completed224Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityAug 2013
NCT01395758ARQ 197Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerP2completed96ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Jul 2011
NCT01204372GATE 1Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic AdenocarcinomaP2completed63Institut du Cancer de Montpellier - Val d'AurelleJun 2010
NCT01320501REALMEExperience of Erlotinib in Patients With Advanced Non-Small Cell Lung CancerP4suspended100National Guard Health AffairsOct 2009
NCT00843531RAD001 and Erlotinib in Patients With Neuroendocrine TumorsP2terminated17University of California, San FranciscoJun 2009
NCT00614653Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic CancerP1completed17M.D. Anderson Cancer CenterJan 2008
NCT00410059BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLCP2completed59M.D. Anderson Cancer CenterNov 2006
NCT01344824Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never SmokersP2completed38UNC Lineberger Comprehensive Cancer CenterMar 2010
NCT01650506Study of Erlotinib and Metformin in Triple Negative Breast CancerP1completed8Columbia UniversityJul 2012
NCT01532011Erlotinib in Combination With Pralatrexate in Advanced MalignanciesP1completed72M.D. Anderson Cancer CenterMar 2012
NCT01182350DIPGMolecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)P2terminated53Karen D. Wright MDSep 2011
NCT01351415NSCLCA Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)P3completed485Hoffmann-La RocheJun 2011
NCT01763385TRACTSErlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain MetastasesP2unknown210Wu Jieping Medical FoundationNov 2012
NCT01116219Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).P2completed149Swiss Cancer InstituteJun 2010
NCT01047059MIMEBMolecular Imaging With Erlotinib and BevacizumabP2completed40University of CologneJan 2010
NCT01284335A Safety Study in Participants With Advanced Solid TumorsP1terminated234Eli Lilly and CompanyJul 2008
NCT02380625EVDMultiple Treatments for Ebola Virus Disease (EVD)P1/P2unknown150Clinical Research Management, Inc.Apr 2015
NCT02146118A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung AdenocarcinomaP2unknown42MedicalLogicApr 2014
NCT02066038EGFRIntermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationP2unknown60Sun Yat-sen UniversityJan 2014
NCT01728181A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic EvaluationP1/P2withdrawn0University of UtahNov 2013
NCT01900652ChimeA Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) ParticipantsP2completed111Eli Lilly and CompanyAug 2013
NCT01059305SCCPhase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the SkinP2terminated10M.D. Anderson Cancer CenterFeb 2011
NCT01482377HER3A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell OriginP1completed145Hoffmann-La RocheDec 2011
NCT01836133ELEMENTAn Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)—completed70Hoffmann-La RocheMay 2013
NCT01456325A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)P3completed494Genentech, Inc.Jan 2012
NCT01328951NSCLCA Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based ChemotherapyP3completed643Hoffmann-La RocheSep 2011
NCT02031744A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung CancerP3completed530Hoffmann-La RocheJan 2014
NCT01652469EMPHASISTesting of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.P3completed81ETOP IBCSG Partners FoundationAug 2012
NCT00304278SCCAStudy of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)P2completed21Southern Illinois UniversityMar 2006
NCT01402089Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsP4completed54Markus JoergerJan 2012
NCT01229150NSCLCRandomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...P2completed89National Cancer Institute (NCI)Oct 2010
NCT00720304Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and NeckP2completed43Case Comprehensive Cancer CenterNov 2007
NCT01608841The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without ErlotinibP2unknown88Taipei Veterans General Hospital, TaiwanJul 2005
NCT02277457PARTISTPersonalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver MutationsEarly P1withdrawn0University of Michigan Rogel Cancer CenterSep 2015
NCT02355431EGFRItacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsP2withdrawn0Incyte CorporationDec 2014
NCT02134886Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionP1terminated48National Cancer Institute (NCI)Jul 2014
NCT02178397FLAREA Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFRP3terminated6Centre Francois BaclesseJun 2014
NCT00591123Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric CardiaP2completed38Translational Oncology Research InternationalDec 2007
NCT01360554ARCHER 1009ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerP3completed878PfizerJun 2011
NCT01294306MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyP2completed80National Cancer Institute (NCI)Feb 2011
NCT01193881RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerP1terminated16National Cancer Institute (NCI)Aug 2010
NCT00442455Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and NeckP3completed53Grupo de Investigación Clínica en Oncología RadioterapiaJan 2006
NCT01153984BIOTECA Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating MutationsP2completed23Hoffmann-La RocheJun 2011
NCT00660816Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung CancerP2completed46Case Comprehensive Cancer CenterJan 2008
NCT02001896Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR MutationP3unknown60Xinjiang Medical UniversityDec 2013
NCT01303029GECASafety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic CancerP2completed120Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Feb 2011
NCT01131429A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR MutationsP2unknown60Chinese PLA General HospitalJun 2010
NCT00994123A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung CancerP1/P2completed162Merrimack PharmaceuticalsFeb 2010
NCT01024413Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 MutationsP3completed256Chinese Society of Lung CancerJul 2009
NCT01835938Clinical Investigation of Erlotinib as an HCV Entry InhibitorP1/P2unknown12University Hospital, Strasbourg, FranceMay 2013
NCT01776684Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA AnalysisN/Aunknown200Samsung Medical CenterJun 2012
NCT00054132Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast CancerP2completed38National Cancer Institute (NCI)Dec 2002
NCT01928160Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or GefitinibP2withdrawn0Vanderbilt-Ingram Cancer CenterJun 2014
NCT00674973A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic CancerP2completed207Hoffmann-La RocheJun 2008
NCT00620269Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC IIIP2unknown212National Cancer Center, KoreaFeb 2008
NCT00570232UAB0718UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck CancerP2completed31University of Alabama at BirminghamDec 2007
NCT01186861Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyP2completed205Astellas Pharma IncMar 2011
NCT01887886EGFRA Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) MutationP3completed10Hoffmann-La RocheDec 2013
NCT01782690An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer—completed338Hoffmann-La RocheMar 2012
NCT00738751Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract CancersP1completed44H. Lee Moffitt Cancer Center and Research InstituteNov 2008
NCT00761345Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic CancerP1completed27Fox Chase Cancer CenterSep 2008
NCT01068587MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous ChemotherapyP1/P2completed31NCIC Clinical Trials GroupJan 2010
NCT01727869Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of CancerP1completed56Regeneron PharmaceuticalsOct 2012
NCT01609543A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsP4completed62Hoffmann-La RocheMay 2012
NCT01578668Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain MetastasesP2completed69Guangzhou Medical UniversityJan 2012
NCT00940316Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal CancerP2completed28Northwestern UniversityJan 2010
NCT02000531PFSProgression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese PopulationP4completed45Hoffmann-La RocheJan 2014
NCT02625168Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLCP2completed25The University of Hong KongJan 2013
NCT01515969TKI258Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)P1terminated9Heather WakeleeJul 2012
NCT01454180Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic TargetsP2completed31Centro Nacional de Investigaciones Oncologicas CARLOS IIIOct 2011
NCT01302808Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerP1completed17University of Texas Southwestern Medical CenterSep 2009
NCT00883779A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung CancerP3completed451Hoffmann-La RocheApr 2009
NCT00738881MARVELPemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerP3terminated23National Cancer Institute (NCI)Oct 2008
NCT01545947Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung CancerP1completed76CelgeneMay 2012
NCT01752205ESCC-307PLAHPaclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous CarcinomaP3unknown120The Affiliated Hospital of the Chinese Academy of Military Medical SciencesNov 2012
NCT01233687AMG 102 and Erlotinib for Advanced Non-Small Cell Lung CancerP1/P2completed49Ahmad TarhiniAug 2011
NCT00942734Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell CarcinomaP2completed49M.D. Anderson Cancer CenterJul 2009
NCT02595450A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer—completed299Hoffmann-La RocheSep 2008
NCT00609804Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on ErlotinibP2completed53SCRI Development Innovations, LLCMar 2008
NCT00257608ATLASA Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)P3completed1,145Genentech, Inc.Jan 2006
NCT00601913Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by SurgeryEarly P1completed24Wake Forest University Health SciencesMar 2008
NCT00283244Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLCP2completed147UNC Lineberger Comprehensive Cancer CenterMar 2006
NCT01990261STARA Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment—terminated33Hoffmann-La RocheMay 2013
NCT01222689Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerP2completed46National Cancer Institute (NCI)Nov 2010
NCT01093222Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaP2completed40National Cancer Institute (NCI)Apr 2010
NCT00975182A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid TumorsP1completed58Genentech, Inc.Sep 2009
NCT00770263Erlotinib and Temsirolimus for Solid TumorsP1completed46Washington University School of MedicineMay 2009
NCT00834678Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast CancerP1/P2completed11Ohio State University Comprehensive Cancer CenterApr 2009
NCT00966472Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLCP1completed24Ottawa Hospital Research InstituteMar 2009
NCT00634725Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by SurgeryP3completed820GERCOR - Multidisciplinary Oncology Cooperative GroupFeb 2008
NCT01515137Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell CarcinomaP1completed47University of PittsburghNov 2005
NCT00124657Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed GliomaP1/P2completed62St. Jude Children's Research HospitalMar 2005
NCT00276575Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid TumorsP1completed65Herbert Hurwitz, MDMar 2005
NCT01259089Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerP1/P2completed38Northwestern UniversityApr 2011
NCT01221077NSCLCStudy of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) GeneP2completed88Astellas Pharma IncApr 2011
NCT01602289A Study of LY2875358 in Japanese Participants With Advanced CancerP1completed17Eli Lilly and CompanyJun 2012
NCT00975767A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung CancerP1terminated126Mirati Therapeutics Inc.Aug 2009
NCT00769067A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenP2completed188PfizerNov 2008
NCT01110876GBMPhase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)P1/P2terminated21M.D. Anderson Cancer CenterJun 2011
NCT01204697TALISMANA Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)P2completed74Hoffmann-La RocheNov 2010
NCT01187901FAPESTA Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsP2completed92University of UtahApr 2010
NCT02044601BATTLE-XRTBiomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)P1/P2withdrawn0M.D. Anderson Cancer CenterJun 2014
NCT01027598Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerP2completed202SCRI Development Innovations, LLCJan 2010
NCT00826449NSCLCDasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)P1/P2completed53M.D. Anderson Cancer CenterFeb 2009
NCT00759928PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid TumorsP1completed48SCRI Development Innovations, LLCOct 2008
NCT00373425RADIANTA Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsP3completed1,252OSI PharmaceuticalsSep 2006
NCT00380029Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder CancerP2completed27UNC Lineberger Comprehensive Cancer CenterMay 2006
NCT01594398ENCORE110Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerP1completed14Syndax PharmaceuticalsMay 2012
NCT01250119A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.P2completed688Hoffmann-La RocheMar 2011
NCT00301418Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic AstrocytomaP1/P2completed11Northwell HealthMar 2006
NCT01342965A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR MutationsP3completed217Hoffmann-La RocheMar 2011
NCT01210911GEMMetformin Combined With Chemotherapy for Pancreatic CancerP2completed120Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Aug 2010
NCT00153803NSCLCErlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)P3completed245Dartmouth-Hitchcock Medical CenterMay 2005
NCT00112736Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaP1/P2completed69National Cancer Institute (NCI)Apr 2005
NCT01116622Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive TractP1completed24Dartmouth-Hitchcock Medical CenterApr 2003
NCT01505413GEMOX-TPhase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic CancerP2completed33Soonchunhyang University HospitalJan 2011
NCT01085838Erlotinib in Higher Risk Myelodysplastic SyndromeP1/P2completed30Groupe Francophone des MyelodysplasiesJul 2010
NCT00425386Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney CancerP2completed60OHSU Knight Cancer InstituteAug 2006
NCT00125359Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung CancerP2completed42Konstantin DragnevAug 2005
NCT01183858CURRENTSA Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)P3completed315Hoffmann-La RocheOct 2010
NCT01038856OSI-TAR-766Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia VeraP2terminated5University of OklahomaDec 2009
NCT00779389Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC FamilyP1completed58University of PittsburghJan 2009
NCT00621049Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLCP2completed112SCRI Development Innovations, LLCDec 2007
NCT00384826Therapeutic Strategy in Advanced Bronchioloalveolar CarcinomaP2completed133Intergroupe Francophone de Cancerologie ThoraciqueSep 2006
NCT00617708S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryP1/P2completed134National Cancer Institute (NCI)Mar 2008
NCT01372384A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor MutationsP2completed6Hoffmann-La RocheJan 2012
NCT01350817TARSEQErlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung CancerP2completed156University Hospital, LimogesJun 2011
NCT00965731Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung CancerP1completed27PfizerJan 2010
NCT00445848S0636S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung CancerP2completed89SWOG Cancer Research NetworkJul 2007
NCT02006043Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)P2unknown54Li ZhangDec 2013
NCT01229813ACT2Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.P3completed233Lund University HospitalOct 2010
NCT01158170NSCLCProphylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)P3unknown200Zhejiang Cancer HospitalJun 2010
NCT00810719Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic CancerP2completed30University of California, DavisApr 2009
NCT00925769ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic CancerP1completed32Hoffmann-La RocheJan 2009
NCT00725634P05538A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaP1completed41AVEO Pharmaceuticals, Inc.Sep 2008
NCT00543842Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal CancerP1completed19M.D. Anderson Cancer CenterDec 2007
NCT00550537Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerP2completed116Vanderbilt-Ingram Cancer CenterOct 2007
NCT00392665Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and NeckP2terminated36Massachusetts General HospitalOct 2006
NCT01287754A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR MutationsP4completed24Hoffmann-La RocheOct 2011
NCT00976677Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung CancerP2terminated10National Cancer Institute (NCI)Jan 2010
NCT00520013CTAAvastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian TumorsP2completed60Dana-Farber Cancer InstituteAug 2007
NCT00452413A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung CancerP1/P2completed65Eli Lilly and CompanyMay 2007
NCT01211483U3-1287Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung CancerP1/P2completed222Daiichi SankyoSep 2010
NCT01192165Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-PaclitaxelP1completed169GlaxoSmithKlineSep 2010
NCT01465815Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)P1/P2withdrawn0OHSU Knight Cancer InstituteDec 2011
NCT01230710A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease ProgressionP4completed51Hoffmann-La RocheMar 2011
NCT00754494Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or AdenomaP2completed45National Cancer Institute (NCI)Jul 2008
NCT00482625Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryP2terminated6National Cancer Institute (NCI)Jun 2007
NCT01664533TIMEAn Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy—completed57Hoffmann-La RocheSep 2011
NCT00473083LUTRAERLSystemic and Topical Treatments for Rash Secondary to Erlotinib in Lung CancerP2completed150British Columbia Cancer AgencyJan 2009
NCT01955421NSCLC EGFR TKIErlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant NsclcP2unknown224Sun Yat-sen UniversityJul 2013
NCT00230126OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung CancerP2completed57Ohio State University Comprehensive Cancer CenterOct 2005
NCT01487174KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyP3terminated8Kadmon Corporation, LLCDec 2011
NCT01009073A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer SubjectsP1completed51AbbVie (prior sponsor, Abbott)Oct 2009
NCT01013831Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the LungP1terminated60National Cancer Institute (NCI)Oct 2009
NCT00702975NSCLCStudy of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic TherapyP2completed35Radboud University Medical CenterSep 2008
NCT00591383Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid TumorsP1unknown10Alaunos TherapeuticsJan 2008
NCT00600587N2Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)P2completed24Guangdong Provincial People's HospitalSep 2007
NCT00696696GESStudy of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic CancerP2completed45NYU Langone HealthSep 2007
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerP1completed43National Cancer Institute (NCI)Jan 2007
NCT00497224Phase II Trial of Erlotinib in Advanced Pancreatic CancerP2completed51University Health Network, TorontoNov 2006
NCT00550836Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic CancerP2completed104Alliance for Clinical Trials in OncologyMar 2009
NCT01565538Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung AdenocarcinomaP2completed123Si-Yu WangDec 2008
NCT00585377Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung CancerP2completed50University of UtahAug 2007
NCT01101334CS-7017Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung CancerP2completed90Daiichi SankyoMar 2010
NCT00955149PSCErlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)P1completed6Mayo ClinicAug 2009
NCT01103375Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant GliomaP1terminated5Wake Forest University Health SciencesMay 2010
NCT01091376RT0901Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)P2unknown75Zhejiang Cancer HospitalJan 2010
NCT00416650Erlotinib in Treating Patients With Advanced Non-Small Cell Lung CancerP2completed16Vanderbilt-Ingram Cancer CenterJul 2002
NCT00637910TAILORTarceva Italian Lung Optimization tRialP3unknown850Fatebenefratelli and Ophthalmic HospitalNov 2007
NCT00590902Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung CancerP2completed81Memorial Sloan Kettering Cancer CenterMar 2002
NCT00408499Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung CancerP1/P2completed64University of California, DavisAug 2006
NCT00280150Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung CancerP1/P2completed46UNC Lineberger Comprehensive Cancer CenterJan 2006
NCT01432119Phase 1 Trial With SIR-Spheres and Cetuximab +/- ErlotinibP1withdrawn0M.D. Anderson Cancer CenterDec 2012
NCT01009203Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell CarcinomaP2terminated13New Mexico Cancer Research AllianceDec 2009
NCT01003938Topotecan With Erlotinib for Topotecan Pretreated Ovarian CancerP2terminated6NYU Langone HealthAug 2009
NCT00983307RTA Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung CancerP2completed17Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityAug 2009
NCT00811993A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid TumorsP1terminated104Hoffmann-La RocheFeb 2009
NCT00737243Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary SiteP2completed289SCRI Development Innovations, LLCAug 2008
NCT00457392A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib AloneP3completed960PfizerJul 2007
NCT00446225EURTACPhase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFRP3completed174Spanish Lung Cancer GroupFeb 2007
NCT01130753Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung CancerP2completed43Samsung Medical CenterJan 2007
NCT00391248PEARLPhase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)P2completed40Ontario Clinical Oncology Group (OCOG)Nov 2006
NCT00440167Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of CapecitabineP3unknown280PD Dr. med. Volker HeinemannJun 2006
NCT01244191Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerP3terminated1,048Daiichi SankyoJan 2011
NCT01251796A Study of ARQ 197 in Combination With ErlotinibP1completed9Kyowa Kirin Co., Ltd.Dec 2010
NCT01026844NSCLCHydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)P1terminated27Massachusetts General HospitalJul 2007
NCT00480584A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic CancerP1completed20H. Lee Moffitt Cancer Center and Research InstituteApr 2007
NCT00314262Phase I/II Study of Chemoprevention With EGFR and COX-2 InhibitorP1/P2completed17Emory UniversityOct 2006
NCT00054275Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast CancerP2completed39Paula Silverman, MDDec 2002
NCT01032070PETEYErlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric EpendymomaP2terminated25OSI PharmaceuticalsSep 2010
NCT01192815Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and NeckP2terminated2Case Comprehensive Cancer CenterJan 2011
NCT00998036Study of Temsirolimus, Erlotinib and Cisplatin in Solid TumorsP1completed9Columbia UniversitySep 2009
NCT00800202A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain MetastasisP2completed91Hoffmann-La RocheApr 2009
NCT00702182Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung CancerP1completed30National Cancer Centre, SingaporeApr 2008
NCT00476476Erlotinib in Women With Squamous Cell Carcinoma of the VulvarP2completed41Dana-Farber Cancer InstituteDec 2006
NCT01996332NSCLCA Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)P2completed1,805Hoffmann-La RocheApr 2004
NCT00509431Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant GliomaP1completed19Jonsson Comprehensive Cancer CenterAug 2006
NCT00369512RAD0503A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell CarcinomaP2completed15University of Alabama at BirminghamAug 2006
NCT00335764Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaP1/P2completed92National Cancer Institute (NCI)Apr 2006
NCT00274833Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeP2completed27David PeereboomOct 2005
NCT01247922Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205P2terminated4OSI PharmaceuticalsMay 2011
NCT01161173TEAMAn Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer—completed347Hoffmann-La RocheApr 2008
NCT00598156ACTChemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- TarcevaP3completed249Lund University HospitalJun 2007
NCT00390429Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsP1/P2completed81University of California, DavisJul 2002
NCT00596648NSCLCA Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)P1/P2completed92ExelixisFeb 2008
NCT00874419ML20981Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 MutationP3completed165Tongji UniversityAug 2008
NCT00977548MDSErlotinib Study for Myelodysplastic Syndrome (MDS)P2completed39H. Lee Moffitt Cancer Center and Research InstituteSep 2009
NCT00718315A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.P3completed201Hoffmann-La RocheApr 2009
NCT00743938A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCP2completed141Bristol-Myers SquibbMar 2009
NCT01149122GEMOXGemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract CarcinomaP3completed266Samsung Medical CenterJan 2009
NCT00349219TORCHTORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung CancerP3completed760National Cancer Institute, NaplesDec 2006
NCT00556322NSCLCA Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)P3completed424Hoffmann-La RocheMar 2006
NCT02036359OncologyErlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung caP2unknown76National Taiwan University HospitalMay 2012
NCT00778167Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerP1/P2completed18National Cancer Institute (NCI)Oct 2008
NCT00536640INNOVATIONSInoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus BevacizumabP2completed224Aktion Bronchialkarzinom e.V.Nov 2007
NCT00392704Treatment of Head & Neck Cancer With Chemotherapy and RadiationP2completed60SCRI Development Innovations, LLCDec 2006
NCT00391586Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the LungP2terminated45New Mexico Cancer Research AllianceJul 2006
NCT00848718MK-2206-003A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)P1completed77Merck Sharp & Dohme LLCMar 2009
NCT01600807OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the PancreasP1/P2withdrawn0Dana-Farber Cancer Institute—
NCT00673049NSCLCTrial Of CP-751, 871 And Erlotinib In Refractory Lung CancerP3terminated583PfizerMay 2008
NCT00592007Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung CancerP2terminated7Lyudmila Bazhenova, M.D.Sep 2007
NCT00096265Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerP3terminated126National Cancer Institute (NCI)Oct 2004
NCT01174043Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid LeukemiaP2completed11Indiana UniversityJul 2010
NCT00855894PENGUINA Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung CancerP2completed41Genentech, Inc.Mar 2009
NCT00652340TP2001-201APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung CancerP2completed120Tragara Pharmaceuticals, Inc.Apr 2008
NCT00353301Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell CarcinomaP2completed25University of Colorado, DenverJul 2006
NCT00585533A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung CancerP2completed40University of UtahJun 2004
NCT00739453A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)P1completed95Astellas Pharma IncOct 2008
NCT00652366A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic CancerP2completed467Hoffmann-La RocheMay 2008
NCT00462995SELECTSurgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)P2completed25University Health Network, TorontoMay 2006
NCT00654420MK-0646A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)P2completed95Merck Sharp & Dohme LLCMar 2008
NCT00602030Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLCP1/P2completed141Syndax PharmaceuticalsJan 2008
NCT01189435Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or GefitinibP2terminated2Memorial Sloan Kettering Cancer CenterAug 2010
NCT00854308A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)P2completed137Genentech, Inc.Apr 2009
NCT00663689Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung CancerP2unknown45Guangdong Provincial People's HospitalMar 2008
NCT00550173A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung CancerP2completed247Eli Lilly and CompanyNov 2007
NCT00448240Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck CancerP2/P3terminated6Henry Ford Health SystemFeb 2007
NCT00265317SUN1058A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib AloneP2completed162PfizerJun 2006
NCT01010945Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic CancerP1completed19OSI PharmaceuticalsFeb 2010
NCT01199068NSCLCCS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)P1completed15Daiichi Sankyo Co., Ltd.Jun 2010
NCT00954525Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic CancerP1completed14Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityJul 2009
NCT00503971Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.P1/P2terminated33Spanish Lung Cancer GroupMay 2008
NCT00642746Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)P2terminated16OHSU Knight Cancer InstituteMar 2008
NCT00577707ECONErlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)P2completed9Memorial Sloan Kettering Cancer CenterNov 2007
NCT00033514Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu OverexpressionP1/P2completed27Jonsson Comprehensive Cancer CenterAug 2001
NCT00692640SAR245408Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid TumorsP1completed35SanofiMay 2008
NCT01998919A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.P2completed154Hoffmann-La RocheAug 2006
NCT00336700A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic CancerP2terminated25Herbert J. Zeh, III MD, FACSJun 2006
NCT00524121Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal CancerP2completed22Roswell Park Cancer InstituteMar 2006
NCT00242502Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By SurgeryP2completed62M.D. Anderson Cancer CenterOct 2005
NCT01069757A Study of ARQ 197 in Combination With ErlotinibP1completed16Kyowa Kirin Co., Ltd.Feb 2010
NCT00940875A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung CancerP2terminated54Hoffmann-La RocheJun 2009
NCT00996515A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor MalignanciesP1completed30New Mexico Cancer Research AllianceJun 2008
NCT00705874Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or LymphomaP1completed172Progen PharmaceuticalsMay 2006
NCT00266097Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract CancerP1completed23UNC Lineberger Comprehensive Cancer CenterAug 2004
NCT00840125Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line TreatmentP2completed4Meir Medical CenterFeb 2009
NCT00777309NSCLCA Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)P2completed167ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Sep 2008
NCT00581789Erlotinib and Sunitinib in NSCLCP1completed11University of Wisconsin, MadisonAug 2007
NCT00393068Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal CancerP2completed62SCRI Development Innovations, LLCFeb 2007
NCT00385996Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung CancerP2completed22Weill Medical College of Cornell UniversityOct 2006
NCT00260364TARGETCombining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic CancerP1/P2completed44Royal Marsden NHS Foundation TrustNov 2005
NCT00147537Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung CancerP1/P2completed282PfizerFeb 2005
NCT00193258Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell CarcinomaP1/P2completed94SCRI Development Innovations, LLCJun 2004
NCT01377376ATTENTIONA Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus ErlotinibP3terminated0Kyowa Kirin Co., Ltd.Jul 2011
NCT01205685Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast CancerP2terminated11Vanderbilt-Ingram Cancer CenterMay 2010
NCT008410357 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer PatientsP2terminated6University of Alabama at BirminghamFeb 2009
NCT00830245A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung CancerP2terminated20Clinical Research Center for Solid Tumor, KoreaJan 2009
NCT00366457Gemcitabine, Bevacizumab and Erlotinib in Pancreatic CancerP2completed32Massachusetts General HospitalAug 2006
NCT00307736Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal CancerP1/P2completed32Massachusetts General HospitalMay 2006
NCT01188707A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung CancerP1/P2terminated5Herlev HospitalOct 2010
NCT01115803A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsP1terminated29Eli Lilly and CompanyMar 2010
NCT00884845Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid TumorsP1completed35PharmaMarJan 2009
NCT00732810SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)P2completed97Merck Sharp & Dohme LLCJul 2008
NCT00447057NSCLCStudy of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)P2completed204Eli Lilly and CompanyMar 2007
NCT00954512Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)P1/P2terminated15Merck Sharp & Dohme LLCSep 2009
NCT00553800NSCLCStudy of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung CancerP2completed32Fox Chase Cancer CenterJul 2007
NCT01332279Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation TherapyP1withdrawn0Fox Chase Cancer CenterApr 2011
NCT00922896Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic CancerP2completed22Gyeongsang National University HospitalJun 2009
NCT00729742MK0646Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)P1completed49Merck Sharp & Dohme LLCFeb 2009
NCT00709826APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic CancerP2completed109Tragara Pharmaceuticals, Inc.Aug 2008
NCT00716456Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to ErlotinibP1/P2completed21Memorial Sloan Kettering Cancer CenterJul 2008
NCT00539617Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by SurgeryP2terminated7University of California, San FranciscoOct 2007
NCT00597597Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast CancerP2terminated11Rush University Medical CenterApr 2007
NCT00603915A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal CancerP2completed20University Health Network, TorontoJun 2006
NCT00113347XRTErlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)P1completed10M.D. Anderson Cancer CenterApr 2005
NCT01108458A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic AdenocarcinomaP2terminated1George Albert FisherJul 2010
NCT00816868A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of LungP2completed62Sun Yat-sen UniversityJan 2009
NCT00564720Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic CancerP2terminated140Hellenic Oncology Research GroupDec 2006
NCT00300586IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung CancerP3completed842Hospices Civils de LyonJun 2006
NCT00086879Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma MultiformeP2completed110European Organisation for Research and Treatment of Cancer - EORTCMay 2004
NCT00784667DuxDual Inhibition of EGFR Signalling Using the Combination of Cetuximab and ErlotinibP2unknown50Austin HealthOct 2008
NCT00777699SAR245409Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid TumorsP1completed80SanofiAug 2008
NCT01557959Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerP2completed45Wake Forest University Health SciencesJul 2007
NCT00278148Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung CancerP1/P2completed32Nathan Pennell, MD, PhDOct 2005
NCT01297101Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy—temporarily not available0Shanghai Chest Hospital—
NCT00118261Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal CancerP1completed17Case Comprehensive Cancer CenterMar 2005
NCT00091026Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic CancerP2completed143National Cancer Institute (NCI)Jul 2004
NCT00079053Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckP1completed19NCIC Clinical Trials GroupMar 2004
NCT00908336NSCLCErlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy RegimenP2unknown70Hospital Arnau de VilanovaMar 2009
NCT00903292EGFRTailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung AdenocarcinomaN/Aunknown52National Cheng-Kung University HospitalMar 2009
NCT00701558A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung CancerP2completed20Hoffmann-La RocheAug 2008
NCT01196078A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung CancerP4completed114Hoffmann-La RocheFeb 2007
NCT00281021Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung CancerP2terminated26University of LouisvilleFeb 2006
NCT00045110Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive MeningiomaP1/P2completed136National Cancer Institute (NCI)Aug 2002
NCT00554775TACTICWBRT & Erlotinib in Advanced NSCLC and Brain MetastasesP2terminated80University College, LondonJan 2008
NCT00461708A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and SurvivalP2completed153Hoffmann-La RocheMay 2007
NCT00970502Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck CancerP1/P2completed15Johnny KaoFeb 2007
NCT00556712NSCLCA Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)P3completed889Hoffmann-La RocheJan 2006
NCT00088959Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung CancerP1completed45National Cancer Institute (NCI)Dec 2003
NCT02013206A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to ChemotherapyP2completed52Hoffmann-La RocheSep 2006
NCT00749567Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung CancerP2terminated13Hellenic Oncology Research GroupJul 2008
NCT00605722A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.P2completed51Hoffmann-La RocheMar 2008
NCT00470535Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic CancerP2terminated18Roswell Park Cancer InstituteJan 2007
NCT00287222Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular CarcinomaP2completed21University of ArkansasFeb 2006
NCT00354549Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLCP2completed104Swiss Cancer InstituteJan 2006
NCT00728000Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic AdenocarcinomaP2withdrawn0University of CincinnatiAug 2008
NCT00873353XELTATrial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer PatientsP2completed32Grupo Gallego de Investigaciones OncologicasMar 2008
NCT00531934A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.P2completed147Hoffmann-La RocheOct 2007
NCT00532441Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract CarcinomasP2terminated25Gabi Chiorean, MDSep 2007
NCT00452075NSCLCErlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for ChemotherapyP2terminated24Rigshospitalet, DenmarkMar 2007
NCT00444015NSCLCPhase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)P1completed34H. Lee Moffitt Cancer Center and Research InstituteMar 2007
NCT00125372Study of Tarceva and Targretin in Stage I-II Lung CancerN/Acompleted12Dartmouth-Hitchcock Medical CenterDec 2005
NCT00708448Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer PatientsP1completed26University of UtahMar 2008
NCT00609999Ph I Dasatinib + Erlotinib in Recurrent MGP1completed47Duke UniversityJan 2008
NCT00603356Phase I Study of OSI-930 and Erlotinib in Cancer TumorsP1completed60Astellas Pharma IncNov 2007
NCT00783471DOPERLODocetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)P2terminated51Hellenic Cooperative Oncology GroupNov 2008
NCT00750698A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibP2terminated8Syndax PharmaceuticalsAug 2008
NCT00405405Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck CancerP1completed13Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityDec 2006
NCT00365391Bevacizumab and Erlotinib in Treating Patients With Advanced Liver CancerP2completed27National Cancer Institute (NCI)Aug 2006
NCT00321815Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung CancerP2completed43PfizerAug 2006
NCT00356889Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsP2completed56National Cancer Institute (NCI)May 2006
NCT00203424Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus ErlotinibP2completed23Translational Oncology Research InternationalJan 2006
NCT00760929NSCLCA Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).P2terminated171Hoffmann-La RocheNov 2008
NCT00606502Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based TreatmentP2completed201Spectrum Pharmaceuticals, IncJan 2008
NCT00988169NSCLCErlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsP2terminated6Memorial Sloan Kettering Cancer CenterSep 2009
NCT00947167A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsP2terminated4Pamela L. KunzMar 2009
NCT00503841Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast CancerN/Aterminated44Barbara Ann Karmanos Cancer InstituteDec 2007
NCT00130520Bevacizumab and Erlotinib Study in Advanced Ovarian CancerP2completed40University of ArizonaJun 2005
NCT00059787Erlotinib Plus Carboplatin and Paclitaxel in Ovarian CarcinomaP2completed56National Cancer Institute (NCI)Apr 2003
NCT00671970MGPhase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)P2completed57Duke UniversityFeb 2007
NCT01135498A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.P2completed90Hoffmann-La RocheNov 2006
NCT00440414NSCLCTrial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)P3completed320Hellenic Oncology Research GroupApr 2006
NCT00276744Individualized Drug Treatment for Treating Patients With Pancreatic CancerP2terminated249Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOct 2005
NCT00140556Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck CancerEarly P1completed28David M. Brizel, MDAug 2005
NCT00126542Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerP2completed35National Cancer Institute (NCI)Apr 2005
NCT00453362A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With ErlotinibP1/P2completed88Genentech, Inc.Dec 2006
NCT00640978Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic CancerP2terminated16M.D. Anderson Cancer CenterMar 2008
NCT00996502Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate CancerP1/P2terminated4Columbia UniversityJul 2006
NCT00365144Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With GemcitabineP2completed36University of California, San FranciscoFeb 2006
NCT00376948Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerP2completed20Barbara Ann Karmanos Cancer InstituteMay 2005
NCT00773383NSCLCA Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.P2terminated35Hoffmann-La RocheNov 2008
NCT00531960A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.P2completed124Hoffmann-La RocheJan 2008
NCT00320073Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid TumorsP1completed41UNC Lineberger Comprehensive Cancer CenterAug 2006
NCT01013506Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast CancerP2withdrawn0Vanderbilt-Ingram Cancer CenterAug 2009
NCT00750555Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck CancerP2terminated4Geisinger ClinicSep 2008
NCT00881166SGI-0470-02Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid TumorsP1completed101Astex Pharmaceuticals, Inc.Nov 2007
NCT00568841ERLOPETErlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)P2unknown40Lung Cancer Group CologneOct 2007
NCT00672243Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeP2completed32Duke UniversityApr 2007
NCT00412217A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell CancerP3terminated94Hoffmann-La RocheNov 2006
NCT00030576Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerP1/P2completed51University Health Network, TorontoNov 2001
NCT00030446Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerP2completed50NCIC Clinical Trials GroupJan 2002
NCT01066884A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung CancerP4completed5Hoffmann-La RocheApr 2009
NCT00791544Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver CarcinomaP1/P2terminated13SanofiNov 2008
NCT00615758Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IVP2completed50Hellenic Oncology Research GroupOct 2006
NCT02694536A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic CancerP3completed80Hoffmann-La RocheAug 2006
NCT01006096Erlotinib for Treatment of PsoriasisP2withdrawn0Northwestern University—
NCT00885066Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic CancerP1completed30Centre Antoine LacassagneMay 2008
NCT00619424A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid TumorsP1completed58GlaxoSmithKlineNov 2007
NCT01130779The Continuation of ErlotinibP2unknown23Samsung Medical CenterAug 2009
NCT00445588Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeP2completed56National Cancer Institute (NCI)Jan 2007
NCT00611468Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid TumorsP1completed29Accelerated Community Oncology Research NetworkJun 2006
NCT00068367S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorP2completed24SWOG Cancer Research NetworkDec 2003
NCT00738335Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain MetastasesP1withdrawn0University of California, San FranciscoJan 2009
NCT00137826Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated MesotheliomaP2completed37Dana-Farber Cancer InstituteFeb 2004
NCT00350753Avastin and Tarceva for Upper Gastrointestinal CancersP2completed126Rigshospitalet, DenmarkJun 2006
NCT00418704NSCLCElderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)—completed100Groupe Francais De Pneumo-CancerologieMay 2006
NCT02774278MERITA Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)P2completed264Hoffmann-La RocheJul 2005
NCT00955695Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung CancerP3unknown242National Cancer Center, KoreaMay 2009
NCT00387322Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsP1/P2completed42University of California, DavisMar 2005
NCT00287989Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung CancerP2completed86Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNov 2004
NCT00903734EGFRAn Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation StatusP1completed16M.D. Anderson Cancer CenterApr 2009
NCT00895687Study of Erlotinib in Combination With BortezomibP1completed24M.D. Anderson Cancer CenterApr 2009
NCT00895362Erlotinib in Combination With CetuximabP1completed65M.D. Anderson Cancer CenterApr 2009
NCT00895128Study of Erlotinib in Combination With DasatinibP1completed65M.D. Anderson Cancer CenterApr 2009
NCT00570375EGFRThe Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic SyndromeP2withdrawn0University of CincinnatiNov 2007
NCT00722969Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerP2unknown48Universitair Ziekenhuis BrusselNov 2007
NCT00642733A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic CancerP4terminated6Hoffmann-La RocheAug 2007
NCT00275132TOPICALErlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerP3completed670University College, LondonApr 2005
NCT00949910NSCLCAn Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)P4completed6,586Hoffmann-La RocheNov 2004
NCT00642473MATERA Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated RashP2completed34Hoffmann-La RocheFeb 2008
NCT01561014Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal JunctionP1completed9Wake Forest University Health SciencesApr 2007
NCT00387894Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaP2terminated6Michael PradosJan 2007
NCT00360360Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary SiteP2completed60SCRI Development Innovations, LLCJul 2006
NCT00370383NSCLCA Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)P2completed100AgennixJul 2006
NCT00600015NSCLCSorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)P2completed166SCRI Development Innovations, LLCFeb 2008
NCT00518011A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.P2completed17Hoffmann-La RocheAug 2007
NCT00574366Erlotinib and Everolimus in Treating Patients With Metastatic Breast CancerP1completed14Vanderbilt-Ingram Cancer CenterDec 2005
NCT00026338Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic CancerP3completed569NCIC Clinical Trials GroupOct 2001
NCT00442507OSI3650Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal JunctionP2terminated6Washington University School of MedicineMar 2007
NCT00193622Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary SiteP2completed50SCRI Development Innovations, LLCApr 2004
NCT00059852Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a TaxaneP2completed61Alliance for Clinical Trials in OncologyJun 2003
NCT00385398QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLCP2withdrawn0University of Medicine and Dentistry of New JerseyJul 2008
NCT02507375NSCLCA Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)P1completed17Hoffmann-La RocheSep 2006
NCT00367601Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung CancerP2completed25Nasser Hanna, M.D.Aug 2006
NCT00611715Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.P2terminated48Vanderbilt-Ingram Cancer CenterNov 2003
NCT00883480SLATIndividualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced AdenocarcinomaN/Acompleted153Spanish Lung Cancer GroupJun 2005
NCT04145570A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditionsP4completed24Quadras Scientific SolutionsOct 2008
NCT00766636Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation TherapyP2terminated5M.D. Anderson Cancer CenterSep 2008
NCT00801385Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to ChemotherapyP2unknown47Yonsei UniversitySep 2008
NCT00351039Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung CancerP1/P2terminated8H. Lee Moffitt Cancer Center and Research InstituteJul 2006
NCT00466687Erlotinib and Bevacizumab in Treating Patients With Stage IV MelanomaP2completed34Vanderbilt-Ingram Cancer CenterSep 2004
NCT00148772PSAStudy of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone TherapyP2completed29Endeavor HealthAug 2005
NCT00522249Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCCP1/P2terminated10The Methodist Hospital Research InstituteMay 2007
NCT00101348Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerP1/P2completed66National Cancer Institute (NCI)Jan 2005
NCT00522938Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerP1/P2terminated2Chroma TherapeuticsDec 2007
NCT00428194Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical CancerP1withdrawn0Masonic Cancer Center, University of MinnesotaJan 2007
NCT00227032Erlotinib in Treating Patients With Progressive Glioblastoma MultiformeP1terminated10UNC Lineberger Comprehensive Cancer CenterSep 2005
NCT00087035Docetaxel and Erlotinib in Treating Older Patients With Prostate CancerP2completed1Jonsson Comprehensive Cancer CenterMay 2004
NCT00989690Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung CancerP3unknown275Istituto Scientifico H. San RaffaeleFeb 2008
NCT00049283Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerP1completed30National Cancer Institute (NCI)Sep 2002
NCT00536861Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung CancerP1completed11Amsterdam UMC, location VUmcMay 2006
NCT00251589A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)P1/P2terminated23Merck Sharp & Dohme LLCJan 2006
NCT00633750Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by SurgeryP2completed50Vanderbilt-Ingram Cancer CenterAug 2002
NCT00536770A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic CancerP2suspended132NovaceaSep 2007
NCT00369889A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic CancerP2completed18Indiana UniversityAug 2006
NCT00283634A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung CancerP2terminated0Millennium Pharmaceuticals, Inc.Aug 2005
NCT00566800Erlotinib in Treating Patients With Barrett EsophagusP1unknown25Kansas City Veteran Affairs Medical CenterJul 2007
NCT00116506Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerP2completed35Dana-Farber Cancer InstituteJan 2005
NCT00495872Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid TumorP1completed204M.D. Anderson Cancer CenterJun 2007
NCT00139620A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic FunctionP1completed39OSI PharmaceuticalsAug 2005
NCT00207077Study of Cetuximab in Combination With Tarceva in Patients With Solid TumorsP1completed33Eli Lilly and CompanyAug 2005
NCT00032110Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal CancerP2completed30National Cancer Institute (NCI)Jan 2002
NCT00030485Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial CancerP2completed0National Cancer Institute (NCI)Jan 2002
NCT00281866Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck CancerP2completed37Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJul 2005
NCT00085839NSCLCErlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2P2completed103OSI PharmaceuticalsFeb 2004
NCT00072631Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung CancerP2completed43OSI PharmaceuticalsNov 2003
NCT00095225A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)P2completed122Genentech, Inc.Jul 2004
NCT00673569Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous TreatmentP2completed40Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSep 2006
NCT00088946Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder CancerP2completed17Jonsson Comprehensive Cancer CenterMay 2004
NCT00410826Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck CancerP2completed204University of WashingtonJun 2006
NCT00678964TIEErlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)P2unknown260LungenClinic GrosshansdorfJun 2006
NCT00032123Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction CancerP2completed0SWOG Cancer Research NetworkJun 2002
NCT00466089Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung CancerP2unknown90Hospital of NavarraMar 2006
NCT00339586First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR GeneP2unknown40Universitair Ziekenhuis BrusselJan 2006
NCT00466284Phase II Trial of Tarceva in Patients With Non-Small Cell Lung CancerP2unknown46Grupo Gallego de Cancer de PulmonJan 2006
NCT00072072Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerP1completed0Jonsson Comprehensive Cancer CenterAug 2003
NCT00337883A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)P2completed110Genentech, Inc.Jul 2003
NCT00126620Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid TumorsP1completed17University Health Network, TorontoSep 2005
NCT00263822Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube CancerP3completed835European Organisation for Research and Treatment of Cancer - EORTCSep 2005
NCT00091663NSCLCA Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)P3completed5,000Genentech, Inc.Aug 2004
NCT00278187Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerP2unknown0Jonsson Comprehensive Cancer CenterJul 2005
NCT00081614A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell CarcinomaP2completed100Genentech, Inc.Mar 2004
NCT00456833Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With ChemotherapyP1completed248Novartis PharmaceuticalsJun 2005
NCT00418327Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem GliomaP1completed48Gustave Roussy, Cancer Campus, Grand ParisJun 2005
NCT00459901Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal CancerP2terminated13Peter KozuchJun 2004
NCT00360854Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem GliomaP1unknown48Children's Cancer and Leukaemia GroupMay 2005
NCT00268684Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLCP3unknown381Tel-Aviv Sourasky Medical CenterMay 2005
NCT00265824DREAMOptimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)P3completed700GERCOR - Multidisciplinary Oncology Cooperative GroupMay 2005
NCT00293436Celecoxib and Erlotinib in Treating Patients With Liver CancerP1/P2withdrawn0University of California, San FranciscoJan 2005
NCT00087269Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionP2terminated110National Cancer Institute (NCI)Dec 2004
NCT00087412S0341S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung CancerP2completed65National Cancer Institute (NCI)Sep 2004
NCT00085280Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerN/Acompleted129National Cancer Institute (NCI)Sep 2004
NCT00049101Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerP1/P2completed0Memorial Sloan Kettering Cancer CenterAug 2002
NCT00217529Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerP1/P2completed0Fred Hutchinson Cancer CenterJun 2004
NCT00033241Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid TumorsP1completed0OSI PharmaceuticalsJul 2001
NCT00077454Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsP1completed95National Cancer Institute (NCI)Feb 2004
NCT00062101Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung CancerP2completed80National Cancer Institute (NCI)Jan 2004
NCT00036647OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerP3completed731OSI PharmaceuticalsNov 2001
NCT00040183OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.P3completed569OSI PharmaceuticalsNov 2001
NCT00047736A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung CancerP3completed0Genentech, Inc.Jul 2001
NCT00060411A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerP1completed24National Cancer Institute (NCI)Jun 2003
NCT00063947Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic CancerP1completed28National Cancer Institute (NCI)May 2003
NCT00060307Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerP2completed40National Cancer Institute (NCI)May 2003
NCT00063895Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckP1/P2completed80National Cancer Institute (NCI)Apr 2003
NCT00055913Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerP1/P2completed58National Cancer Institute (NCI)Mar 2003
NCT00030537Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast CancerP2completed0National Cancer Institute (NCI)Nov 2001
NCT00039494Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain TumorsP2completed171National Cancer Institute (NCI)Dec 2002
NCT00049166Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat CancerP1completed48National Cancer Institute (NCI)Oct 2002
NCT00055770Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck CancerP1/P2completed45National Cancer Institute (NCI)Oct 2002
NCT00047762Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal CancerP1completed0Genentech, Inc.Oct 2002
NCT00109265A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyP2completed0Genentech, Inc.May 2001
NCT00047346Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver DysfunctionP1completed24National Cancer Institute (NCI)Aug 2002
NCT00047333Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically RemovedP2terminated80National Cancer Institute (NCI)Aug 2002
NCT00054496Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma MultiformeP2unknown73The Cleveland ClinicAug 2002
NCT00045526Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach CancerP2completed48National Cancer Institute (NCI)Jun 2002
NCT00042835Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung CancerP1terminated48National Cancer Institute (NCI)May 2002
NCT00039182Erlotinib in Treating Patients With Malignant Mesothelioma of the LungP2completed55National Cancer Institute (NCI)May 2002
NCT00042809Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid TumorsP1completed40National Cancer Institute (NCI)May 2002
NCT00031993Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the CervixP2completed51National Cancer Institute (NCI)Mar 2002
NCT00033462Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerP2completed78National Cancer Institute (NCI)Mar 2002
NCT00030498Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionP1completed75National Cancer Institute (NCI)Dec 2001

Erlotinib clinical trials: frequently asked questions

How many Erlotinib clinical trials are there?
698 Erlotinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 9 are actively recruiting participants. 458 are marked completed.
Are Erlotinib clinical trials recruiting in 2026?
Yes — 9 Erlotinib trials are actively recruiting in 2026, with 6 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Erlotinib being studied for?
Erlotinib is being studied for Non-Small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Carcinoma, Non-Small-Cell Lung and 727 more. The trials are grouped by indication on this page.
What phase is Erlotinib in?
Erlotinib clinical trials span 14 Phase 4, 77 Phase 3, 352 Phase 2, 143 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Erlotinib clinical trials?
The lead sponsor across the most Erlotinib trials is National Cancer Institute (NCI), with 263 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Erlotinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai:

Erlotinib overviewErlotinib evidence & publications